documents incorporated reference specified portions registrant 's definitive proxy statement filed commission pursuant regulation connection annual meeting incorporated reference part iii report based closing price per share excludes shares registrant 's common stock held executive officers directors stockholders whose ownership exceeds common stock outstanding february exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrant february march registrant implemented twoforone stock splits form stock dividends share per share amounts periods presented restated reflect splits part iitem business forwardlooking statements risk factors report includes forwardlooking statements particular statements expectations beliefs plans objectives assumptions future events performance contained incorporated reference report based forwardlooking statements current expectations future events believe expectations reasonable forwardlooking statements inherently subject risks uncertainties many beyond control actual results may differ materially suggested forwardlooking statements various reasons including discussed report heading risk factors given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof undertake specifically decline obligation update statements publicly announce results revisions statements reflect future events developments overview gilead sciences inc independent biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases worldwide five marketed products focus research clinical programs antiinfectives including antivirals antifungals antibacterials headquartered foster city california marketing operations ten countries including united states australia eight european countries endeavor grow existing portfolio products proprietary clinical development programs internal discovery programs active product acquisition inlicensing strategy internal discovery activities include identification new molecular targets target screening medicinal chemistry also expertise liposomal drug delivery technology use develop drugs safer easier patients tolerate effective incorporated delaware june five products currently marketed us countries worldwide viread approved sale us use combination antiretroviral agents treatment hiv infection european union use combination antiretroviral agents treatment hiv infection patients experiencing early virological failure ambisome approved sale countries treatment lifethreatening fungal infections countries prevention infections market ambisome major countries europe copromote ambisome us fujisawa healthcare inc tamiflu sold corporate partner hoffmannla roche countries treatment influenza approved us prevention influenza vistide approved sale countries treatment cmv retinitis aids patients daunoxome approved sale countries treatment aidsrelated kaposi 's sarcoma us sales force promotes viread ambisome vistide daunoxome international sales force europe australia promotes viread ambisome daunoxome also corporate partners distributors promoting ambisome vistide daunoxome countries studying adefovir dipivoxil two ongoing phase iii trials treatment infection hepatitis b virus hbv filed regulatory approval us europe based results date believe adefovir dipivoxil potential address many limitations current hbv therapies notably drug resistance associated longterm therapy november announced entered agreement osi pharmaceuticals inc osi valued million cash stock agreed sell oncology assets osi transaction completed december recorded gain million transaction allow us focus continue strengthen core expertise infectious diseases transaction sold osi pipeline clinical candidates oncology nx gs l gs related intellectual property well boulder colorado operations including clinical research drug development operations infrastructure facilities upon completion transaction osi paid us million cash shares osi common stock osi also pay us additional million either cash combination cash osi common stock upon achievement certain milestones osi related development nx advanced oncology product candidates sold transaction manufacturing agreement using active ingredients supplied us osi produce nx gs l two liposomal products included sale manufacturing facility san dimas california marketed products products developed commercially available include viread drug treating hiv infection ambisome drug treating preventing lifethreatening fungal infections tamiflu drug treating preventing influenza vistide drug treating cytomegalovirus cmv retinitis aids patients daunoxome drug treating aidsrelated kaposi 's sarcomahow products sold indications approved vary product country region sold earned revenues approximately million sales royalties products amount sales ambisome generated aggregate product sales royalty revenues approximately million total revenues earned revenues sales royalties products us million million million outside us earned revenues sales royalties products million million million begin recognizing revenues commercial sales viread november expect revenues earn sales viread comprise increased percentage total revenues decrease percentage total revenues sales ambisome although predict certainty future revenues either ambisome viread viread viread formulation nucleotide analogue reverse transcriptase inhibitor tenofovir df dosed one mg pill day part combination therapy treat hiv infection adults viread approved sale us use combination antiretroviral agents treatment hiv infection sale european union use combination antiretroviral agents treatment hiv infection patients experiencing early virological failure sell viread us us sales force major european countries european sales forces see marketing sales september february respectively announced week week effectiveness safety results study week pivotal phase iii clinical trial evaluating viread component combination therapy treatmentexperienced patients sites us europe australia designed study provide us conclusive data safety effectiveness viread study patients randomly divided two groups one group patients viread added existing therapy first weeks twothirds enrolled patients one group patients given placebo addition existing therapy first weeks onethird enrolled patients patients given viread addition existing therapy second weeks results demonstrate following weeks weeks treatment viread reduced patients ' serum hiv dna measure amount hiv weeks average approximately logcopiesml meets primary endpoint trial compared reduction approximately log copiesml patients received placebo weeks approximately log copiesml viread suppressed hiv viral loads copiesml weeks approximately patients compared patients received placebo weeks patients viread increased patients ' cd cell counts weeks weeks patients received placebo cd cell counts decrease weeks increase cd cell count important indication hiv drug improving patient 's immune system rates discontinuation use weeks equivalent patients using viread patients using placebo viread cause significant increase serious side effects relative placebo weeks safety profile viread weeks similar weeks three percent patients receiving viread developed resistance viread weeks additionally viread treatment weeks significantly reduced development mutations associated class antiretroviral agents known protease inhibitors compared placebo group september presented results week phase ii dose ranging clinical trial tenofovir df treatmentexperienced patients study patients received one three doses tenofovir df mg mg mg placebo addition existing combination therapy week patients receiving placebo switched mg dose trial showed patient population following weeks treatment higher doses tenofovir df associated lower levels serum hiv dna compared placebo week higher doses tenofovir df associated lower levels serum hiv dna compared baseline measurement point greatest reduction observed mg group study also showed weeks dosing tenofovir df result increase serious adverse events compared lower doses tenofovir df phase iii results study combined completed phase ii results support belief viread important treatment option difficult treat treatmentexperienced patients data study week data study together data clinical trials formed basis us marketing application us food drug administration fda approved october european union application approved february continuing evaluate viread treating patients prior hiv therapy january completed enrollment patients study phase iii clinical trial compare safety effectiveness treatment patients prior hiv therapy viread combination lamivudine tc efavirenz safety effectiveness treatment stavudine dt lamivudine efavirenz study provide additional information viread treating patient population successful form basis supplemental marketing application european union use one major challenges treating hivinfected patients drug resistance many existing therapies treating hiv infection aids rely similar drug processes patients developed resistance one drug often develop resistance drugs within class believe viread approved regulatory authorities could important drug treatmentexperienced patients available data shown patients develop rapid resistance viread viread effective treating patients developed resistance therapies certain however resistance data may obtain upon completion phase iii clinical trials show similar resistance characteristics week week data study data obtained limited phase ii clinical trialsanother major concern hiv treatment convenience dosing combination therapies positive impact health hiv infected patients require patients take numerous different drugs drugs require multiple doses every day many timing restrictions results inconvenience patients also contributes patients missing doses adhering therapy viread approved administered oncedaily oral pill schedule may appealing hivinfected patients physicians low discontinuation rate observed viread supports belief december discontinued developing adefovir dipivoxil treating hivinfected patients decision followed recommendation fda advisory panel approve mg dose adefovir dipivoxil treating hiv infection due primarily concerns kidney toxicity developed late trials well desire additional evidence treatment benefits tenofovir df structure activity similar adefovir dipivoxil viread associated kidney toxicity shown superior treatment benefits clinical trials certain kidney toxicity issues occurred later stages phase iii clinical trials adefovir dipivoxil hiv arise viread viread faces substantial competition number drugs treat hiv infection aids currently sold advanced stages clinical development including products currently sold us among major pharmaceutical companies significant competitors hivaids market glaxosmithkline bristolmyers squibb hoffmannla roche pfizer merck boehringeringelheim abbott laboratories see competition exclusive worldwide license patent rights related technology viread institute organic chemistry biochemistry part academy sciences czech republic rega stichting vzw together iocbrega obligated pay net revenues sales viread iocbrega us european union countries product approved patent protection see collaborative relationships iocbrega ambisome ambisome liposomal formulation amphotericin b amphotericin b powerful antifungal agent known ability attack kill broad variety lifethreatening fungal infections also serious side effects including kidney toxicity patients likely suffer fungal infections patients weakened immune systems including transplant patients patients infected hiv cancer patients undergoing chemotherapy studies show delivering amphotericin b proprietary liposomal formulation ambisome reduces rate severity kidney toxicity injection related reactions allows patients receive higher effective doses amphotericin b ambisome approved sale countries including us european union rest europe australia canada several countries middle east latin america asia ambisome primarily used treating patients known lifethreatening fungal infections countries ambisome approved including us authorized promote ambisome first line treatment patients remaining countries ambisome approved use indication conventional amphotericin b therapy fails conventional amphotericin b used thus second line therapy addition ambisome approved us countries first line therapy patients certain symptoms presumed fungal infections us four countries ambisome also approved first line treatment acute cryptococcal meningitis aids patients addition ambisome approved treatment preventing fungal infections liver transplant patients four countries additional types transplant patients russia ambisome approved treating parasitic infection called visceral leishmaniasis countries us copromote ambisome fujisawa healthcare domestic sales force agreement fujisawa entitles us percentage revenues generated sales provides fujisawa purchases ambisome us manufacturing cost see collaborative relationships fujisawa major european countries australia sell ambisome international sales force certain countries sell ambisome independent distributors see marketing sales corporate partner sumitomo studying ambisome clinical trials japan drug yet approved marketing sumitomo exclusive right sell ambisome japan receive percentage revenues receive sales see collaborative relationshipssumitomo revenues ambisome europe expect case foreseeable future major european countries sell ambisome currency country revenues us dollars could therefore decrease value currencies decrease relative value us dollar ambisome several current expected competitors conventional amphotericin b markets ambisome approved first line therapy conventional amphotericin b made bristol myers squibb company numerous generic manufacturers many countries ambisome prescribed conventional amphotericin b therapy failed used caspofungin product developed merck received us marketing approval january european union marketing approval october voriconazole developed pfizer inc received marketing approval european union march us fda deemed pfizers ' new drug application nda voriconazole approvable lipidbased amphotericin b products approved us throughout europe including abelcet sold elan corporation amphotec sold intermune pharmaceuticals inc products compete ambisome primary secondary therapy generally offered prices less ambisome 's price see competition tamiflu tamiflu oral pill treatment prevention influenza b tamiflu class prescription drugs called neuraminidase inhibitors act disabling common strains flu virus preventing virus spreading patient tamiflu originally approved fda october treatment uncomplicated influenza adult patients november approved fda prevention influenza adults adolescents years older december tamiflu approved japan treatment influenza adults us treatment children young one year old march application european union market tamiflu treatment prevention influenza recommended approval ascientific advisory committee responsible agency used approved treatment influenza tamiflu shown reduce duration flu adults average days reduce severity flu symptoms incidence secondary infections taken approved prevention influenza studies shown tamiflu effective preventing development flu common side effects associated tamiflu mild nausea vomiting hoffmannla roche corporate partner developed tamiflu us exclusive right sell tamiflu began selling tamiflu us november may hoffmannla roche submitted marketing authorisation application european union seeking tamiflu approved centralized procedure european union application withdrawn hoffmannla roche enable hoffmannla roche submit additional data application refiled hoffmannla roche february january hoffmannla roche announced due production problems liquid suspension form tamiflu approved treatment children young one year old available expected available flu season production issues affect availability tablet form tamiflu adults adolescents years older expect current production issues material effect earnings receive percentage net revenues hoffmannla roche generates sales tamiflu see collaborative relationshipshoffmannla roche several products available treat flu time shown effective safe neuraminidase inhibitors relenza antiflu drug sold glaxosmithkline neuraminidase inhibitor approved fda drug delivered inhaled powder direct competition tamiflu tamiflu currently fdaapproved neuraminidase inhibitor available pill believe method delivery gives tamiflu competitive advantage relenza aware however biocryst pharmaceuticals developing neuraminidase inhibitor peramivir potential delivered oncedaily pill tamiflu taken twice daily treatment flu biocryst pharmaceuticals receives approval product also direct competition tamiflu see competition tamiflu marketed alternative influenza vaccinations believe influenza vaccinations remain effective method preventing flu vistide vistide antiviral medication treatment cmv retinitis patients aids cmv retinitis condition caused viral infection characterized lesions form patient 's retina condition affects persons weakened immune systems common patients aids left untreated cmv retinitis lead blindness vistide approved fda june european regulatory authorities may based clinical trials demonstrating drug delays progression cmv retinitis lesions newly diagnosed patients previously treated patients failed therapies sell vistide us us sales force see marketing sales outside us pharmacia corporation exclusive right sell vistide vistide approved sale countries european union well several countries throughout world pharmacia corporation pays us percentage revenues generates sales vistide see collaborative relationshipspharmacia corporation vistide competes number drugs also treat cmv retinitis drugs include ganciclovir drug sold intravenous oral formulations hoffman laroche ocular implant bausch lomb incorporated valganciclovir oral prodrug formulation ganciclovir also marketed hoffman laroche foscarnet intravenous drug sold astrazeneca formivirsen drug injected directly eye sold cibavision see competition significant side effect associated use vistide kidney toxicity due side effect certain precautions must taken vistide used certain circumstances vistide may used time vistide given patient patient must first tested warning signs kidney toxicity patient warning signs kidney toxicity vistide may given patient combination certain solutions reduce possibility kidney toxicity addition vistide may given patients receiving drugs cause kidney toxicity patients receiving drugs known cause kidney toxicity must discontinue taking drugs wait seven days using vistide certain animal studies cidofovir active ingredient vistide caused cancer side effects dosing limitations competitive disadvantage vistide cidofovir active agent vistide considered part us government strategy dealing potential bioterror attacks involving smallpox lifethreatening infectious disease laboratory tests cidofovir demonstrated activity strains virus causes smallpox current clinical trials diluted smallpox vaccine conducted national institute allergy infectious diseases cidofovir potential treatment vaccinia infection potential adverse reaction sometimes caused smallpox vaccine additionally us national institutes health holds ind allows emergency use cidofovir smallpox outbreaks predict whether us countries may stockpile vistide treatment smallpox exclusive worldwide license patent rights related technology cidofovir iocbrega obligated pay net revenues sales vistide products containing cidofovir iocbrega see collaborative relationshipsiocbrega daunoxome daunoxome liposomal formulation anticancer agent daunorubicin received approval sell daunoxome us countries first line therapy treating patients suffer certain types hivassociated kaposi 's sarcoma kaposi 's sarcoma disease characterized widely disseminated lesions theskin mucous membranes lymph nodes viscera life threatening patients suffering aids daunoxome uses proprietary liposomal technology deliver safer effective doses daunorubicin disease site studies shown daunoxome may actually locate accumulate patient 's tumor allow patient receive higher concentrations daunorubicin disease site could obtained equivalent dose nonliposomal daunorubicin market daunoxome us abroad sales forces certain foreign countries distributors see marketing sales products late stage clinical trials developing adefovir dipivoxil large latestage human clinical trials treating patients infected hbv based results date applied approval adefovir dipivoxil treatment hbv infection us european union march exclusive commercial rights market cidecin european countries cidecin antibacterial developed cubist pharmaceuticals inc phase ii phase iii clinical trials cubist completed two successful pivotal phase iii clinical trials treatment complicated skin soft tissue infections caused grampositive bacteria one pivotal phase iii clinical trial treatment communityacquired pneumonia caused gram positive bacteria cidecin successful meeting primary endpoint evaluating strategies applying regulatory approval cidecin europe currently expect file application determine certainty ongoing future clinical trials adefovir dipivoxil cidecin successful successful whether fda regulatory agencies approve drugs marketing adefovir dipivoxil hepatitis b hepatitis b caused highly contagious hbv hbv infection cause acute liver failure patients develop chronic hbv infection many years lead complications cirrhosis liver cancer liver failure result death according current estimates world health organization centers disease control approximately million people worldwide million people us chronic hbv infection one million deaths attributable hbv infection worldwide year hepatitis b one ten leading causes death worldwide adefovir dipivoxil nucleotide analogue reverse transcriptase inhibitor adefovir dipivoxil disables hbv interfering activity enzyme known hbv polymerase necessary hbv replicate two separate phase iii clinical trials evaluate safety effectiveness adefovir dipivoxil pills treating patients chronic hbv infection phase iii trials designed randomized doubleblind placebocontrolled studies conducted clinical sites us canada europe australia southeast asia study evaluating adefovir dipivoxil treating patients test positive hbv e antigen common type chronic hepatitis b trial study evaluating adefovir dipivoxil daily mg treating patients type hbv known precore mutant hepatitis b precore mutant hbv common southeast asian mediterranean countries june november respectively announced interim complete analyses week effectiveness safety results study week pivotal phase iii clinical trial evaluating safety effectiveness adefovir dipivoxil mg dose daily monotherapy compared placebo patients chronic hbv infection hbv e antigen positive sites united states canada europe australia southeast asia designed study provide us data safety effectiveness mg dose adefovir dipivoxil secondary objective mg dose adefovir dipivoxil study patients randomly divided three groups approximately equal size one group received mg dose adefovir dipivoxil one group received mg dose adefovir dipivoxil one group received placebo results adefovir dipivoxil mg daily dose demonstrate following weeks treatment adefovir dipivoxil improved liver histology patients compared patients received placebo meets primary endpoint trial change liver histology important marker disease progression patients chronic hbv infection adefovir dipivoxil caused seroconversion disappearance hepatitis b e antigen marker hbv replication appearance antibodies specific antigen patients treated adefovir dipivoxil weeks compared patients placebo adefovir dipivoxil reduced patients ' serum hbv dna measure amount hbv average approximately log copiesml meets endpoint trial compared reduction approximately log copiesml patients received placebo adefovir dipivoxil reduced amino alanine transferase alt levels iul compared reduction iul patients received placebo fortyeight percent patients treated adefovir dipivoxil mg achieved normalization alt levels compared patients receiving placebo alt levels indicators disease severity adefovir dipivoxil cause significant increase serious side effects relative placebo evidence kidney abnormalities either adefovir dipivoxil placebo groups similar discontinuation rates patients using adefovir dipivoxil patients using placebo patients receiving adefovir dipivoxil observed developed resistance mutations adefovir september announced week preliminary effectiveness safety results study week pivotal phase iii clinical trial evaluating safety effectiveness adefovir dipivoxil dose mg daily monotherapy compared placebo patients precore mutant hbv hbv e antigennegative virus compensated liver function liver functioning near normal levels sites australia canada france greece israel italy southeast asia designed study provide us conclusive data safety effectiveness mg daily dosage adefovir dipivoxil precore mutant hbv study patients randomly divided two groups one group patients treated adefovir dipivoxil mg daily twothirds enrolled patients one group patients given placebo onethird enrolled patients results demonstrate following weeks treatment adefovir dipivoxil mg daily dose adefovir dipivoxil improved liver histology patients compared improvements patients received placebo meets primary endpoint trial change liver histology important marker disease progression patients chronic hbv infection adefovir dipivoxil reduced patients ' serum hbv dna average approximately log copiesml meets endpoint trial compared reduction approximately log copiesml patients received placebo adefovir dipivoxil reduced alt levels iul compared reduction iul patients received placebo seventytwo percent patients treated adefovir dipivoxil achieved normalization alt levels compared patients receiving placebo alt levels indicators disease severity adefovir dipivoxil cause significant increase serious side effects relative placebo evidence kidney abnormalities either adefovir dipivoxil placebo groups equivalent discontinuation rates patients using adefovir dipivoxil patients using placebo patients receiving adefovir dipivoxil observed developed resistance mutations adefovir vaccine available prevent transmission hbv cure patients become chronically infected virus expect vaccine becomes widely available incidence new hbv infection decrease existing therapies treating patients infected hbv include drugs epivirhbv form lamivudine sold glaxosmithkline introna form interferon alpha b sold schering plough epivirhbv orally administered antiviral drug prevents hbv replicating patients introna injectable drug provide reduction amount virus blood patients often associated side effects believe fda approves adefovir dipivoxil epivirhbv would significant competition certain adefovir dipivoxil approved treatment hbv infection determine adefovir dipivoxil would competitive epivirhbv see competition case hiv infection drug resistance serious problem drugs treat hbv infection example one year therapy epivir hbv patients develop resistance lamivudine increasing four years therapy based published data lamivudine resistance occurs percent hivhbv coinfected patients two years lamivudine therapy percent patients treated four years conducted provided support clinical trials designed provide information whether adefovir dipivoxil could provide treatment option patients lamivudine resistant hbv infection data four clinical studies patients lamivudineresistant hbv infection treated adefovir dipivoxil mg daily demonstrate treating patients lamivudineresistant hbv infection adefovir dipivoxil reduce serum hbv dna levels study patients lamivudineresistant chronic hbv infection compensated liver function liver functioning normal near normal levels reductions weeks serum hbv dna patients treated adefovir dipivoxil log copiesml similar patients treated adefovir dipivoxil combination lamivudine mg daily log copiesml greater patients treated lamivudine mg daily log copiesml study liver transplant patients lamivudineresistant chronic hbv infection treated adefovir dipivoxil weeks serum hbv dna levels reduced log copiesml weeks log copiesml weeks administration adefovir dipivoxil sustained reductions weeks median reduction hbv dna log copiesml study patients lamivudineresistant chronic hbv infection decompensated liver disease liver longer functioning normally leading signs symptoms liver disease treated adefovir dipivoxil added ongoing lamivudine treatment median reduction serum hbv dna approximately log copiesml weeks treatment study weeks treatment adefovir dipivoxil added existing lamivudine therapy patients coinfected lamivudineresistant chronic hbv hiv infections statistically significant mean reductions serum hbv dna log copiesml four studies patients markers indicating abnormal liver function prior treatment showed improvements clinical markers liver function treatment adefovir dipivoxil available data date demonstrated resistancemutation associated adefovir dipivoxil hbv suggesting development resistance adefovir dipivoxil hbv patients may slow infrequent believe resistance profile adefovir dipivoxil could make important drug treating chronic hbv infection certain however resistance data may obtain continuing phase iii clinical trials adefovir dipivoxil continue show resistance characteristics described viread discontinued development adefovir dipivoxil mg treatment hiv infection due safety benefit concerns arising studies studies shown adefovir dipivoxil significantly effective hbv hiv allowing us use lower doses treatment hiv infection mg doses adefovir dipivoxil shown significant kidney toxicity clinical trials date clinical data phase iii clinical trials mg dose adefovir dipivoxil demonstrated mg dose met primary endpoints studies certain results phase iii clinical studies adefovir dipivoxil mg dose demonstrate satisfaction fda regulatory agencies adefovir dipivoxil safe effective treatment chronic hbv infection hepatitis b infection common china southeast asian countries december received clinical trials permit initiate phase clinical trials china commenced clinical trials june limited regulatory expertise china manufacturing marketing capacity china southeast asia therefore continue rely assistance third parties activities also difficult protect patents countries could adversely affected unable obtain adequate patent protection adefovir dipivoxil china southeast asia part approval commence phase clinical trials china adefovir dipivoxil granted class designation adefovir dipivoxil ultimately approved sale chinawould give us years market exclusivity adefovir dipivoxil respect competitors may otherwise able begin clinical development adefovir dipivoxil following approval exclusive worldwide license patent rights related technology adefovir dipivoxil iocbrega would obligated pay net revenues sales adefovir dipivoxil iocbrega countries product patent protection including us member states european union see collaborative relationshipsiocbrega cidecin cidecin daptomycin injection investigational antibacterial compound developed cubist pharmaceuticals inc january entered agreement cubist granting us exclusive commercial rights cidecin european countries arrangement cubist responsible ongoing clinical trials product responsible european regulatory filings countries exclusive commercial rights believe arrangement represents strategic opportunity us cidecin falls within therapeutic focus antiinfectives product approved could sold expanded version existing european sales marketing infrastructure laboratory tests suggested cidecin may effective rapidly killing grampositive bacteria including become resistant current therapies grampositive bacterial infections include complicated skin soft tissue infections bacteremia endocarditis infection valves heart complicated urinary tract infections pneumonia osteomyelitis infection bone bone marrow case hiv hbv resistance existing antibacterial therapy become significant problem treating infections laboratory tests confirmed clinical trials cidecin could useful drug treating serious infections assurance however results complicated skin soft tissues infections confirmed clinical trials cubist evaluated currently evaluating cidecin multiple phase ii phase iii trials treatment complicated skin soft tissue infection communityacquired pneumonia resistant enterococcal infections complicated urinary tract infection two completed pivotal phase iii trials treatment complicated skin soft tissue infections caused grampositive bacteria cidecin achieved primary endpoint statistical equivalence comparator agents currently considered optimal antibiotic standards care complicated skin soft tissue infections data two trials also demonstrated patients successfully treated cidecin required fewer days intravenous therapy patients successfully treated comparator agents cidecin 's safety profile similar comparator agents january cubist announced primary endpoint demonstrating noninferiority active comparator agent achieved first cubist 's two phase iii trials investigating safety effectiveness cidecin treatment communityacquired pneumonia requiring hospitalization february cubist announced results phase ii clinical trial cidecin demonstrating primary endpoint demonstrating differences microbiologic clinical cure rates cidecin versus comparator agent achieved treatment complicated urinary tract infection caused grampositive bacteria march cubist announced soon begin phase iii clinical trial cidecin treatment endocarditis infection heart valves bacteremia infection bloodstream cubist stated intends file nda us cidecin indication complicated skin soft tissues infections involving susceptible resistant grampositive organisms agreement cubist require cubist continue conduct complete additional clinical trials cubist successfully completes phase iii clinical trials uses complicated skin soft tissue infection could seek regulatory approval uses territory would exclusive commercial rights indications territory predict outcome clinical trials cidecin cubist evaluate cidecin additional uses currently evaluating options filing marketing authorization cidecin european union received indications regulatory authorities european union application seeking marketing approval cidecin single indication treatment complicated skin soft tissue infection may approved currently expect file application accurately predict whether cidecin meet primary endpoints clinical trials indications complicated skin soft tissue infection whether conducted cubist us whether able obtain regulatory approval cidecin europe file marketing authorization application cidecin europe approved would sell cidecin european sales marketing infrastructure cubist also developing oral formulation daptomycin yet human clinical trials agreement cubist would give us exclusive commercial rights territory oral formulation daptomycin developed cubist required pay milestone payments cubist based upon certain development goals relating clinical development regulatory approval cidecin oral formulation daptomycin also required pay royalties cubist based upon sales make cidecin oral formulation daptomycin see collaborative relationshipscubist product preclinical development intend begin phase clinical trials gs novel nucleotide analogue reverse transcriptase inhibitor gs viread processed body yield active chemical tenofovir within cells however chemical composition gs may allow cross cell membranes easily viread gs tenofovir may present much higher levels within cells result gs may greater potency viread may inhibit lowlevel hiv replication cells otherwise difficult reach reverse transcriptase inhibitors certain phase clinical trial subsequent phase ii phase iii clinical trials may conduct gs completed successfully within specified time period may choose fda may require us delay suspend clinical trials gs time appears patients exposed unacceptable health risk gs appear sufficient treatment benefit science research scientists foster city san dimas california engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs therapeutic focus areas infectious diseases total research development expenses million compared million million nucleotide analogues scientists working proprietary nucleotide analogues develop treatments viral infections compounds treat viral infections interfering activity certain enzymes necessary virus grow example vistide nucleotide analogue cytosine inhibits activity enzyme cmv essential virus spread viread adefovir dipivoxil nucleotide analogues work inhibiting activity reverse transcriptase enzyme necessary replication hiv viread hbv adefovir dipivoxil believe small molecule nucleotide analogues offer advantages therapeutics advantages include molecules demonstrated ability work infected uninfected cells could enable us develop drugs treat patient infected virus also prevent healthy person becoming infected first place drugs developed molecules shown treatment activity patient longer periods time available drugs could enable us develop drugs require less frequent dosing thus convenient patients given complexity drug development certain drug candidates develop science advantages even develop drug candidates advantages fda regulatory agencies could reject marketing approval drug candidates reasons including safety benefit concerns liposomes also scientists focused applying proprietary liposomal drug delivery technology develop safer effective convenient drugs liposomes submicroscopic structures made phospholipids basic components human cell walls hollow spheres drugs packed believe influence way compounds released distributed body placing liposomes turn improve safety treatment benefits compounds example developed ambisome incorporating amphotericin b liposome preclinical studies shown ambisome delivers amphotericin b manner results fewer side effects improved treatment benefits conventional amphotericin b including concentrating drug site infection extending time drug remains blood stream prolong therapeutic effect reducing kidney toxicity injection related reactions clinical studies demonstrate ambisome persist longer blood stream lower kidney toxicity injection related reactions compared conventional amphotericin b current strategy use liposomal technology compounds develop internally identify appropriate compounds developed third parties use technology compounds developed third parties appropriate technology include like amphotericin b proven therapeutic benefits suffer significant side effects suffer dosing administration problems believe use liposomal technology improve safety drugs maintaining even improving therapeutic benefits identified certain generic compounds compounds protected patents proprietary compounds owned third parties may benefit substantially liposomal technology begun formulation studies compounds addition discussed continue discuss collaborative relationships companies develop liposomal formulations compounds hiv protease inhibitors evaluating number small molecule compounds known protease inhibitors potential treatment hiv infection protease inhibitors act interfering activity protease enzyme like reverse transcriptase necessary replication hiv conducted number preclinical experiments compounds demonstrated potent antiviral activity scientists trying increase safety convenience reduce resistance concerns compounds antiviral research undertaking additional research area treatment viral diseases many efforts focus potential targets hiv therapeutic drugs marketing sales established us sales force therapeutic specialists began selling vistide also marketing subsidiaries united kingdom germany italy spain france portugal greece netherlands australia sales professionals promote sell viread ambisome daunoxome us europe ambisome daunoxome australia vistide us ambisome also sold fujisawa us copromote product canada pharmacia corporation promotes sells vistide countries outside us hoffmannla roche promotes sells tamiflu everywhere sold us sales force promotes viread vistide direct contact physicians hospitals clinics healthcare providers involved treatment patients hiv ambisome infectious disease specialists hospitals home health care providers cancer specialists daunoxome cancer specialists hospitals us sales force supported field support force marketing sales support staff based headquarters foster city california international sales forces europe australia international marketing subsidiaries headed general manager oversees operations markets served subsidiary personnel located mainly europe including medical financial regulatory manufacturing human resources personnel support international sales marketing operations subsidiaries also assist obtaining regulatory approvals countries located sell viread vistide daunoxome us viread ambisome daunoxome europe wholesalers specialty distributors turn sell products physicians hospitals clinics pharmacies healthcare providers countries outside us agreements thirdparty distributors including distributors certain countries marketing operations promote sell distribute ambisome daunoxome international distribution agreements generally provide distributor exclusive right sell ambisome daunoxome particular country several countries specified period time intend enter similar arrangements thirdparty distributors outside us promotion sale anddistribution viread increased sales force us devoting additional marketing resources us due approval viread expand coverage healthcare professionals treating hivinfected patients also significantly increased size commercial operations europe manage commercialization viread european union current intention retain commercial rights adefovir dipivoxil hbv infection us europe sell marketing partners distributors asia rest world retain significant commercial rights adefovir dipivoxil hbv infection product approved would need use additional marketing resources sell product cidecin approved marketing europe believe given profile product target market additional sales marketing positions need added us viread vistide returnable original unopened containers one year beyond expiration date damaged received customer customers may return ambisome daunoxome shelf life expired product damaged defective customer receives ambisome approved shelf life months us months european countries daunoxome shelf life weeks us european countries viread shelf life months us approved shelf life european union additionally certain governmental agency customers state aids drug assistance programs entitled receive discounts required provide rebates state medicaid programs date returns rebates discounts material fujisawa establishes return policy ambisome north america hoffmannla roche establishes return policy tamiflu collaborative relationships part business strategy establish collaborations companies assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring companies products rights products technologies complementary business accounting relationships found note consolidated financial statements existing collaborative relationships follows hoffmannla roche september entered collaboration agreement hoffmannla roche develop commercialize therapies treat prevent flu agreement granted hoffmannla roche exclusive worldwide rights proprietary influenza neuraminidase inhibitors including tamiflu october fda approved tamiflu marketing november hoffmannla roche began selling tamiflu december received license fees milestone payments hoffmannla roche totaling million relating execution agreement regulatory filings approvals tamiflu hoffmannla roche also funded research development costs tamiflu including reimbursement us million period january december addition agreement hoffmannla roche responsible pricing promoting selling tamiflu worldwide basis hoffmannla roche pays us percentage net revenues sales tamiflu certain circumstances amount hoffmannla roche pays us may reduced example cost materials use manufacture tamiflu increases receive payments recognize revenue hoffmannla roche quarter following quarter sales made hoffmannla roche make milestone payments us tamiflu approved sale european union agreement hoffmanla roche terminates countrybycountry basis later expiration patent coverage tamiflu ten years first commercial sale hoffmannla roche right terminate agreement entirety countrybycountry basis prior expiration time upon months notice fujisawa entered agreement fujisawa providing exclusive right promote sell ambisome countries except us canada fujisawa exclusive right promote sell ambisome canada right copromote ambisome fujisawa us fujisawa primary responsibility promoting selling ambisome receive approximately net revenues sales ambisome us copromotion efforts receive payments recognize revenue fujisawa month following month fujisawa 's sales made would required pay fujisawa revenues connection sales ambisome significant asian markets including japan korea taiwan china india manufacture ambisome sales fujisawa purchases ambisome us sale us price equal cost manufacture product sale canada cost plus specified percentageour agreement fujisawa terminates last patent covering ambisome us japan expires iocbrega entered agreements iocbrega relating nucleotide compounds discovered institutions december paid iocbrega million reduce royalties payable upon sales viread adefovir dipivoxil royalty rate us european union countries products approved patent protection agreements amendments agreements received iocbrega exclusive right manufacture use sell nucleotide compounds covered agreements countries patent protection required pay iocbrega net revenues generated sales viread adefovir dipivoxil net revenues generated sales vistide products containing compounds subject minimum royalty payments countries patent protection required pay royalties iocbrega sales viread adefovir dipivoxil required pay net revenues generated sales vistide products containing compounds currently making quarterly payments iocbrega based upon percentage sales vistide viread pay additional amounts upon commercial sales adefovir dipivoxil amortize million payment made december estimated commercial lives viread adefovir dipivoxil reduce reported earnings products agreements iocbrega terminate countrybycountry basis later expiration patent coverage product licensed agreements ten years first commercial sale iocbrega may terminate licenses agreements particular product key markets make sales product within months regulatory approval countries cubist january entered agreement cubist giving us exclusive commercial rights european countries oral injectable formulations cubist 's investigational antibacterial compound daptomycin formulations include cidecin intravenous formulation daptomycin currently phase iii clinical trials treatment bacterial infections agreement cubist required complete certain key clinical trials cidecin responsible regulatory filings products territory cidecin approved marketing territory responsible marketing cidecin territory paid upfront fee cubist million time signed agreement paid milestone payments cubist totaling million achievement milestones relating safety effectiveness cidecin treatment complicated skin soft tissue infection caused grampositive bacteria may required make additional payments cubist million certain goals related clinical development regulatory approval cidecin oral formulation daptomycin achieved required pay cubist percentage revenues sales daptomycin products territory cubist desires grant commercial rights oral injectable daptomycinrelated product certain countries including country joins eu cubist must offer us commercial rights priority basis cubist obligated continue preclinical development oral formulation daptomycin would obligation pursue clinical development formulation appropriate agreement expires country country basis respect product developed upon later ten years first commercial sale product country date patent coverage product pharmacia corporation august entered agreement pharmacia corporation relating vistide agreement received million signing million upon approval vistide marketing europe addition agreement pharmacia corporation exclusive right market sell vistide countries outside us right first negotiation competitive products responsible maintaining patents cidofovir required sell bulk cidofovir pharmacia corporationwe required sell bulk cidofovir pharmacia corporation pharmacia corporation pay us percentage net sales vistide products developed collaboration agreement receive payments recognize revenue pharmacia corporation quarter following quarter sales made pharmacia corporation holds shares common stock purchased connection agreement pharmacia corporation may sell shares acquire additional shares stock without approval june agreement pharmacia corporation expires countrybycountry basis patent coverage vistide expires ten years first commercial sale vistide countries product covered patent addition pharmacia corporation may terminate agreement upon six months notice upon notice countrybycountry basis three months applying marketing approval competitive product sumitomo pharmaceuticals co ltd entered agreement sumitomo pharmaceuticals co ltd gave sumitomo exclusive right develop market ambisome japan sumitomo paid us million time entered agreement million march sumitomo made regulatory filing japan terms agreement sumitomo required make payment million us ambisome approved sale japan sumitomo required pay us percentage revenue generate sales ambisome ambisome approved sale japan would manufacture ambisome sale sumitomo japan price would charge sumitomo supply ambisome percentage revenues would required pay us would determined price ambisome japan agreement terminates later ten years sumitomo begins selling ambisome japan date last patent ambisome japan expires eyetech pharmaceuticals march entered agreement eyetech pharmaceuticals inc relating nx known eye oligonucleotide eyetech currently developing treatment agerelated macular degeneration received million upfront license fee eyetech upon execution agreement terms agreement eyetech received exclusive right develop commercialize eye entitled additional cash payments eyetech million eyetech reaches certain eye development milestones product successfully commercialized eyetech pay us royalties worldwide sales product part transaction received fiveyear warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors required license agreement university technology corporation transferred warrant university technology corporation right acquire shares therefore currently hold warrant purchase shares agreement expires upon later ten years first commercial sale product developed date last patent expires agreement glaxosmithklineselex may entered agreement giving glaxosmithkline nonexclusive right use selex technology five years identify aptamers agreement glaxosmithkline would required pay us fee time enter additional agreement glaxosmithkline would required make payments us based achieving certain goals relating regulatory approval product develop based aptamer glaxosmithkline would required pay us percentage revenues may generate sales product develop based theglaxosmithkline would required pay us percentage revenues may generate sales product develop based aptamer agreement terminates may except glaxosmithkline extend agreement additional one year periods case glaxosmithkline would required pay us appropriate fee glaxosmithkline terminate agreement earlier time days notice us somalogic inc november entered agreement somalogic inc company formed larry gold founder nexstar pharmaceuticals inc nexstar relating selex technology agreement gave somalogic exclusive right use selex technology make sell vitro diagnostic products diagnostic products used person animal assigned sold somalogic certain patents materials relating vitro diagnostics including robotic selex machines right use drug discovery technology subject agreement internally study diseases drug development clinical trial programs somalogic paid us first installment fee time entered agreement second final installment november agreement terminates later country country basis patent coverage drug discovery technology expires november archemix corporation october entered agreement archemix corporation relating selex technology agreement gave archemix exclusive rights selex process including therapeutic commercial applications extent already licensed preexisting agreements right use selex technology internal research purposes archemix paid us million required pay us million required license agreement university technology corporation paid million payment pay million payment university technology corporation received warrants purchase archemix stock required license agreement university technology corporation transferred warrant university technology corporation osi pharmaceuticals inc november entered agreement osi pharmaceuticals inc sale osi oncology assets transaction completed december recorded gain million agreement sold osi pipeline clinical candidates oncology related intellectual property well boulder colorado operations including clinical research drug development operations infrastructure facilities three clinical development candidates sold osi nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor osi paid us million cash approximately million shares osi common stock entitled additional payments osi million either cash combination cash osi common stock osi reaches certain development milestones nx advanced oncology product candidates sold osi manufacturing agreement produce osi liposomal formulations nx gs l two liposomal products sold osi manufacturing facility san dimas california osi assumed rights obligations amended agreement glaxo wellcome glaxosmithkline glaxo relating nx license agreement glaxo relating gs l license agreement relating gs southern research institute international distribution agreements various agreements distributors europe asia latin america middle east africa grant distributors exclusive right sell ambisome cases daunoxome particular country countries specified period time agreements also provide collaborative efforts us distributor obtaining regulatory approval product particular country marketing product country agreements establish price distributor must pay product require us deliver quantities product ordered distributor intend enter similar distribution agreements viread countries promote sell directly academic consulting relationshipsto supplement research development efforts part regular business enter arrangements universities medical research institutions arrangements often provide us rights patents patent applications technology owned institutions return payments fees relating use rights university technology corporation ongoing collaborative arrangement relating selex technology university technology corporation technology holding company university colorado boulder arrangement university colorado boulder given us present future rights inventions covered patents patent applications selex technology improvements selex technology makes discovers oligonucleotides molecules makes using selex technology results certain research computer software related selex technology required pay university colorado boulder revenues generate sales selexderived products amounts receive third party based upon sales third parties selexderived products payments receive third parties result certain arrangements third parties develop sell selexderived products manufacturing ambisome daunoxome manufacture ambisome daunoxome commercial quantities two separate adjacent facilities san dimas california ambisome produced one buildings daunoxome produced separate building medicines control agency united kingdom us food drug administration approved commercial production ambisome daunoxome facility produced import ambisome daunoxome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging european union elsewhere use commercially available materials equipment manufacture products currently obtain amphotericin b use manufacture ambisome daunorubicin hcl distearoylphosphatidylcholine use manufacture daunoxome cholesterol use manufacture ambisome daunoxome single approved suppliers ambisome currently freeze dried san dimas manufacturing facility sold freezedried product given demands projections growth ambisome use currently using third party fill freeze dry product evaluating feasibility installing additional freeze drying capacity san dimas unable locate appropriate third parties install validate additional freeze drying capacity san dimas ability increase ambisome sales would diminished manufacturing liposomal products particularly complex process new liposomal product develop require unique complex variations manufacturing process antiviral products hire third parties manufacture antiviral drugs clinical commercial purposes including vistide adefovir dipivoxil viread hoffmannla roche manufactures tamiflu commercialscale manufacturing facilities antiviral products qualified fda 's current good manufacturing practices current plans establish facilities using third parties certain perform obligations effectively timely basis third parties perform effectively timely clinical trials regulatory filings could delayed could unable deliver products customers timely basis would adversely affect operating results january hoffmannla roche announced due production problems liquid suspension form tamiflu approved treatment children young one year old available expected available flu season two suppliers approved fda manufacture cidofovir used vistide one suppliers approved european union manufacture cidofovir use vistide second cidofovir supplier qualified assure supplies single fda emea approved supplier final drug product manufacture active ingredient viread three contract manufacturers approved fda european union manufacture viread tablets one contract manufacturer approved agencies second contract manufacturer qualified manufacture viread tablets assure supplies seeking qualification us theeuropean union two contract manufacturers active ingredient adefovir dipivoxil one contract manufacturer final adefovir dipivoxil drug product commercial supply manufacturing sites use interrupted reason ability ship products would impaired would adversely affect us viread adefovir dipivoxil tablets used clinical trials manufactured two contract manufacturing sites manufacturing either sites interrupted reason ability maintain clinical supplies would impaired would adversely affect us future antiviral products need develop additional manufacturing capabilities establish additional third party suppliers order manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities candidates approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future antiviral products ability conduct largescale clinical trials meet customer demand commercial products would adversely affected believe technology use manufacture products compounds proprietary antiviral products disclosed necessary aspects technology contract manufacturers enable manufacture products compounds us agreements manufacturers intended restrict using revealing technology certain manufacturers comply restrictions addition manufacturers could develop technology related work perform us may need manufacture products compounds could required enter agreement manufacturer wanted use technology allow another manufacturer use technology manufacturer could refuse allow us use technology could demand terms use technology acceptable believe compliance material environmental regulations related manufacture products patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection us internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows actual estimated expiration dates us europe primary patents patents may issue pending applications cover compounds marketed products product candidates us patent expiration european patent expiration products viread ambisome tamiflu vistide daunoxome product candidates adefovir dipivoxil cidecin na applications patents pending patents applications issue would patent protection dates indicated would instead rely patents expire earlier example european patent viread issue patents expire provide protection commercial rights cidecin united states method use patents general method use patents provide level protection composition matter patents patents covering vistide viread adefovir dipivoxil cidecin held third parties acquired exclusive rights patents agreements parties see collaborative relationships patents cover active ingredients ambisome daunoxome instead hold patents liposomal formulations compounds also protect formulations trade secrets patent filings covering forms adefovir dipivoxil china certain asian countries although applications pending various asian countries including china relate specific forms formulations adefovir dipivoxil asia major market hbv therapies may obtain patents compounds many years obtain marketing approval limits time prevent companies developing compounds therefore reduces value product however apply patent term extensions example extensions patents vistide granted us number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third party allowing us use technology certain required could obtain license third party technology could obtain one reasonable cost able obtain required license could adversely affected patent applications confidential least period time including sometimes us patent issues may pending patent applications patents eventually issue prevent us developing selling certain products unless obtain license use patented technology patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation reexamination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection addition pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products developing also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements would adequate remedies breach trade secrets otherwise become known independently discovered competitors research development agreements inventions discovered certain cases become jointly owned us corporate partner cases become exclusive property one us difficult determine owns particular invention disputes could arise regarding inventions competition products development programs target number diseases conditions including viral fungal bacterial infections many commercially available products diseases large number companies institutions spending considerable amounts money resources develop additional products treat diseases current products compete available products based primarily product performance safety tolerability acceptance doctors patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability various modes dosing products market future also compete products offered competitors competitors introduce data shows improved characteristics products improve increase marketing efforts simply lower price products sales products could decrease also certain products develop future compare favorably products offered competitors existing future products compare favorably new products developed competitors ability competitive also depends upon ability attract retain qualified personnel obtain patent protection otherwise develop proprietary products processes secure sufficient capital resources substantial period takes develop product ambisome several current expected competitors conventional amphotericin b markets ambisome approved first line therapy conventional amphotericin b made bristol myers squibb company numerous generic manufacturers many countries ambisome prescribed conventional amphotericin b therapy failed used caspofungin product developed merck received marketing approval january us sold cancidas received marketing approval european union october expect face significant competition caspofungin voriconazole developed pfizer inc received marketing approval european union march pfizer filed application marketing approval voriconazole us fda deemed nda approvable expect face significant competition voriconazole lipidbased amphotericin b products approved us throughout europe including abelcet sold elan corporation amphotecother lipidbased amphotericin b products approved us throughout europe including abelcet sold elan corporation amphotec sold intermune pharmaceuticals inc products compete ambisome primary secondary therapy generally offered prices less ambisome 's price viread faces substantial competition number drugs treat hiv infection aids currently sold advanced stages clinical development including products currently sold us among major pharmaceutical companies significant competitors hivaids market glaxosmithkline bristolmyers squibb hoffmannla roche pfizer merck boehringeringelheim abbott laboratories tamiflu competes relenza antiflu drug sold glaxosmithkline relenza neuraminidase inhibitor delivered orallyinhaled dry powder addition biocryst pharmaceuticals developing neuraminidase inhibitor antiflu drug peramivir represent significant competition fda approves drug may administered oncedaily pill opposed tamiflu must taken twice daily treatment certain tamiflu compare favorably drug based performance price length dosing side effects criteria biocryst pharmaceuticals commenced phase iii clinical trial peramivir unclear product may market vistide competes number drugs also treat cmv retinitis drugs include ganciclovir widely prescribed drug treatment cmv retinitis sold hoffman laroche intravenous formulation treatment cmv retinitis oral formulation prevention treatment cmv retinitis bausch lomb incorporated device implanted patient 's infected eye releases ganciclovir directly infected area valganciclovir oral prodrug formulation ganciclovir marketed hoffman laroche received marketing approval us april netherlands september treatment cmv retinitis hoffman laroche stated expects paneuropean approval mid foscarnet injectable drug treatment cmv retinitis sold astrazeneca formivirsen drug injected directly eye sold cibavision adefovir dipivoxil approved treat hbv infection lamivudine significant competition lamivudine drug developed glaxosmithkline collaboration biochem pharma lamivudine sold us europe china several countries shown effective treating patients infected hbv drugs approved awaiting approval treatment kaposi 's sarcoma us europe including one sold liposomal formulation drugs compete expected compete daunoxome number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together biopharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs anticipate face increased competition future competitors introduce new products market new technologies become available determine existing products new products competitors develop effective effectively marketed sold develop competitive products could render technology products obsolete noncompetitive recover money resources used develop products government regulation operations activities subject extensive regulation numerous government authorities us countries us drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion products result regulations product development product approval process expensive time consuming fda must approve drug sold us general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug 's potential safety benefits submit data fda investigational new drug application ind seeking approval test compound humans clinical trials fda accepts investigational new drug application study drug human clinical trials determine drug safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug given small number healthy human subjects patients test safety dose tolerance pharmacokinetics metabolism distribution excretion phase ii drug given limited patient population determine effect drug treating disease best dose drug possible side effects safety risks drug phase iii compound appears effective safe phase ii clinical trials phase iii clinical trials commenced confirm results phase iii clinical trials longterm involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug uncommon drug appears promising phase ii clinical trials fail rigorous reliable phase iii clinical trials fda approval process believe data phase iii clinical trials show adequate level safety effectiveness file nda fda seeking approval sell drug particular use fda review new drug application often hold public hearing independent advisory committee expert advisors asks additional questions regarding drug committee makes recommendation fda binding fda generally followed fda fda agrees compound required level safety effectiveness particular use allow us sell drug us use unusual however fda reject application believes drug safe enough effective enough believe data submitted reliable conclusive point process development drug could stopped number reasons including safety concerns lack treatment benefit certain clinical trials conducting including viread hiv infection adefovir dipivoxil chronic hbv infection conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require us complete additional testing provide additional data information improve manufacturing processes procedures facilities require extensive postmarketing testing surveillance monitor safety benefits product candidates determine new drug application contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug approvals also withdrawn fda believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug manufacturing facilities drug sell including companies manufacture drugs us well must approved fda subject periodic inspections fda foreign establishments manufacture products sold us must also approved fda subject periodic regulatory inspection manufacturing facilities located california including san dimas facility foster city facility also must licensed state california compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs may designated fast track products fda may eligible priority six month review accelerated approval case viread drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug seek priority six month review accelerated approval adefovir dipivoxil determine whether granted impact would timing likelihood approval adefovir dipivoxil also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds research development activities eliminate risk accidental contamination injury materials misuse accidents involving materials could lead significant litigation fines penalties drugs also subject extensive regulation outside us european union centralized approval procedure authorizes marketing product countries european union includes major countries europe procedure used decentralized system approval one country european union used obtain approval another country european union simplified application process approval centralized procedure pricing reimbursement approvals also required countries vistide viread approved european union centralized procedure using centralized approval procedure adefovir dipivoxil tamiflu reviewed centralized procedure approved europe pricing reimbursement insurance companies health maintenance organizations hmos thirdparty payors governments seek limit amount charge drugs example certain foreign markets pricing negotiations often required obtain approval product us expect continue number federal state proposals implement drug price control addition managed care organizations becoming common us continue seek lower drug prices announcement proposals efforts cause stock price lower proposals adopted revenues would decrease ability sell drugs also depends availability reimbursement governments private insurance companies governments insurance companies often demand rebates predetermined discounts list prices expect products developing particularly aids indications subject reimbursement issues certain products obtain regulatory approval reimbursed government insurance companies regulatory approval prices generally required foreign countries particular certain countries condition approval product agreement seller sell product certain price country past required price reductions connection product approval certain regulatory authorities future establish lower prices regulatory action reducing price products one country practical effect requiring us reduce prices countries certain developing countries significantly affected hiv aids parallel importing generic competition may occur adversely affect revenues sales market share vireademployees february fulltime employees believe good relations employees risk factors evaluating business carefully consider following risks addition information report following risks could materially adversely affect business operating results financial condition viread new drug may gain significant market acceptance viread new drug faces extremely competitive marketplace currently drugs sold us treatment hiv infection aids potential drugs late stages clinical development competitors potential competitors substantially greater resources resources include greater experience promoting marketing hiv drugs superior product development capabilities financial scientific manufacturing marketing managerial human resources order viread successful establish marketplace competitors ' drugs early determine viread achieve significant market acceptance never marketed sold drug treatment hiv infection might successful never operated managed marketing sales operation size attempted penetrate potential market size might effectively predict whether phase iii clinical study demonstrate viread safe effective combination therapy patients prior hiv therapy compared competitor 's drug long term use viread may reveal safety issues development resistance viread patients marketing efforts unsuccessful clinical trial results demonstrate viread safe effective patients prior hiv therapy viread turns safety resistance issues may unsuccessful convincing physicians prescribe viread patients government reimbursers private insurance companies may pay viread prescribed patients prior hiv therapy viread gain significant market acceptance results operations suffer significant reduction ambisome viread sales would significantly reduce operating income could require us scale back manufacturing operations reduce sales force ambisome sales years ended december approximately million million million total revenues expect revenues sales ambisome continue constitute substantial part total product revenues least viread sales year ended december approximately million total revenues represents sales access programs us europe initial product sales us following us regulatory approval viread october expect product sales viread constitute substantial part total revenues foreseeable future accordingly foreseeable future expect continue rely heavily sales ambisome viread support existing manufacturing sales infrastructure provide operating income offset significant portion administrative research development expenditures significant reduction sales ambisome viread whether result introduction competitive products otherwise would hurt business would scale back manufacturing operations reduce sales force several products market compete ambisome generally priced lower ambisome expect face significant competition new antifungal products including caspofungin product developed merck voriconazole product developed pfizer inc merck received us marketing approval january european union marketing approval october caspofungin pfizer received european union marketing approval march filed us marketing approval application deemed approvable fda viread faces competition number drugs treat hiv infection aids including products currently sold us history losses expect operate loss foreseeable future may never profitable never profitable fullyear operating basis may never become profitable operating basis december accumulated deficit approximately million losses resulted principally expenses associated research development programs lesser extent sales general administrative expenses product sales royalty revenues derived sales ambisome viread vistide daunoxome royalty arrangements related tamiflu ambisome vistide develop drugs treat hiv infection aids related conditions therefore changes regulatory commercial environment hiv infection aids therapies could harm business several products products development address hiv infection aids related conditions products include viread hiv infection aids vistide cmv retinitis daunoxome hivassociated kaposi 's sarcoma develop products based upon current policy current marketplace hiv infection aids therapies well prediction future policy future marketplace therapies business subject substantial risk policies markets change quickly unpredictably ways could impair ability obtain regulatory approval commercial acceptance products operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis achieve continued compliance could delay commercialization products products develop sell must approved subject extensive regulation fda comparable agencies countries continuing clinical trials ambisome viread currently approved additional uses also conducting clinical trials adefovir dipivoxil anticipate conduct variety clinical trials file marketing approval additional products next several years corporate partner cubist pharmaceuticals conducting clinical trials cidecin may conduct clinical trials cidecin future products may fail receive marketing approval timely basis part due failure cidecin meet primary endpoint cubist pharmaceuticals ' first pivotal phase iiiclinical trial cidecin treatment communityacquired pneumonia caused grampositive bacteria reevaluating regulatory strategy cidecin expect file marketing approval application cidecin certain adefovir dipivoxil cidecin approved fda european union regulatory authorities countries whether adefovir dipivoxil cidecin may receive marketing approvals place limitations uses failures delays limitations well regulatory changes actions recalls could delay commercialization products adversely affect results operations addition even products marketed products manufacturers subject continual review later discovery previously unknown problems products manufacturing production thirdparty manufacturers may result restrictions products manufacture products including withdrawal products market fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution results clinical trials approval products uncertain may delayed prohibited selling products number potential products reached development stage potential products include adefovir dipivoxil cidecin required demonstrate safety effectiveness products develop intended use extensive preclinical studies clinical trials order obtain regulatory approval products results preclinical early clinical studies always accurately predict results later largescale clinical trials several reasons including preliminary results may indicative effectiveness clinical trials may achieve desired result clinical trials may reveal unduly harmful side effects may show drugs less effective drugs delivery systems desired indications even successfully completed largescale clinical trials may result marketable products several reasons including potential products shown safe effective regulatory authorities disagree results design studies trials potential products difficult develop commercially viable products january cubist pharmaceuticals announced first pivotal phase iii clinical trial cidecin treatment communityacquired pneumonia caused grampositive bacteria cidecin successful meeting primary endpoint november fda advisory committee recommended approval application approve mg dose adefovir dipivoxil treat hiv infection kidney toxicity associated mg dose well desire additional data major concerns committee following recommendation informed fda would approve application unless obtained additional data satisfied concerns raised committee based discussions terminated development adefovir dipivoxil treatment aids used using mg doses adefovir dipivoxil phase iii clinical trials adefovir dipivoxil hbv infection seeking regulatory approval mg dose clinical results date indicate lower doses result kidney toxicity experienced mg adefovir dipivoxil effective treating hbv infection lower doses certain however lower doses safe enough sufficient treatment benefits receive fda approval viread class drugs adefovir dipivoxil yet observed kidney toxicity clinical trials viread kidney toxicity clinical trials adefovir dipivoxil hiv infection arise later stages clinical trials certain similar toxicity issues arise later ongoing clinical trials viread number companies industry suffered similar setbacks advanced clinical trials despite promising results earlier trials end may unable develop additional marketable products delays enrolling patients developing suitable protocols clinical trials could increase costs delay regulatory approvals rate completion clinical trials depend rate patient enrollment substantial competition enroll patients clinical trials drugs development competition delayed clinical trials past addition recent improvements existing drug therapy particularly hiv hbv infections may make difficult us enroll patients clinical trials patient population may choose enroll clinical trials sponsored companies choose alternative therapies delays planned patient enrollment result increased development costs delays regulatory approvals clinical trials must carried protocols acceptable regulatory authorities committees responsible clinical studies sites studies conducted may delays preparing protocols receiving approval may delay either start finish clinical trials addition feedback regulatory authorities results earlier stage clinical studies might require modifications delays later stage clinical trials types delays result increased development costs delayed regulatory approvals product development efforts may yield marketable products due results studies trials failure achieve regulatory approvals market acceptance proprietary rights others manufacturing issues success depends ability successfully develop obtain regulatory approval market new pharmaceutical products significant portion research conduct involve new unproven technologies development product requires substantial technical financial human resources even product successfully completed potential products may appear promising various stages development yet fail reach market number reasons including lack sufficient treatment benefit unacceptable toxicity preclinical studies clinical trials failure receive necessary regulatory approvals existence proprietary rights third parties inability develop manufacturing methods efficient costeffective capable meeting stringent regulatory standards product sales occur outside us currency fluctuations may impair financial results significant majority sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition hedge respect foreign accounts receivable past hedge exposure impact fluctuating foreign exchange rates forecasted sales effective january begun use forward contracts hedge percentage forecasted international sales primarily sales denominated euro currency expect use forward contracts reduce impact foreign currency fluctuations future results product development expenses cause operating expenses fluctuate quarter quarter clinical trials required regulatory approval products extremely expensive difficult accurately predict control amount timing expenses quarter quarter uneven unexpected spending programs causes operating results fluctuate quarter quarter depend relationships companies research funding clinical development sales marketing performance revenues failure maintain relationships would negatively impact business rely number significant collaborative relationships major pharmaceutical companies research funding clinical development andor sales marketing performance include collaborations fujisawa healthcare glaxosmithkline hoffmannla roche pharmacia corporation eyetech pharmaceuticals inc sumitomo pharmaceuticals co inc certain countries rely international distributors sales ambisome countries intend rely international distributors sales viread addition collaboration agreement cubist pharmaceuticals inc commercialize cubist 's antibacterial drug cidecin several european countries following regulatory approval cubist responsible ongoing clinical development cidecin accordingly control rely cubist 's clinical trials regulatory filings cidecin cidecin meet primary end point cubist 's first phase iii clinical trial communityacquired pneumonia caused grampositive bacteria expect file marketing approval application european union complicated skin soft tissue infection indication cidecin achieved success phase iii clinical trials ongoing clinical trials support regulatory approval cubist required conduct additional clinical trials may choose conduct trials expense reliance collaborative relationships poses number risks including able control whether corporate partners devote sufficient resources programs products disputes may arise future respect ownership rights technology developed corporate partners disagreements corporate partners could lead delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenue existing products including tamiflu ambisome could decline january hoffmannla roche announced due production problems liquid suspension form tamiflu approved treatment children young one year old available expected available flu season production issues affect availability tablet form tamiflu adults adolescents years older expect current production issues material effect earnings rights market ambisome us canada limited agreement fujisawa failure fujisawa effectively market ambisome may reduce revenues rights market ambisome us canada subject agreement fujisawa terms agreement sole marketing rights ambisome countries except us canada must pay royalties connection sales significant asian markets including japan copromote ambisome fujisawa us manufacture ambisome sale us canada sell ambisome fujisawa cost us cost plus specified percentage canada fujisawa collects revenues ambisome sales us pays us approximately net sales success ambisome us dependent primarily efforts fujisawa canada success ambisome depend entirely fujisawa fujisawa fails efforts potential revenues sales ambisome may substantially reducedfailure hoffmannla roche effectively market tamiflu would reduce potential revenues hoffmannla roche sole responsibility promoting selling tamiflu worldwide basis control activities therefore relying efforts hoffmannla roche revenues receive sale tamiflu hoffmannla roche dedicate sufficient resources promotion tamiflu hoffmannla roche fails marketing efforts royalties receive sale tamiflu would decrease would adversely affected inability establish future successful collaborative relationships may impair financial results may seek future collaborative relationships corporate partners fund research development expenses develop commercialize potential products anticipate revenues collaborative agreements continue affected existing agreements well timing drug development programs corporate partners may able negotiate acceptable collaborative arrangements future arrangements negotiate may successful fail establish additional collaborative relationships required undertake research development marketing manufacturing proposed products expense discontinue reduce activities existing products products development may accepted physicians insurers patients adefovir dipivoxil cidecin approved marketing would established market ability products achieve sustain market acceptance depend receipt scope regulatory approvals whether government authorities managed care organizations adequately reimburse patients use products addition need convince medical patient advocacy community effectiveness products treating disease safety products administered patients advantages products competitive products physicians patients patient advocates payors medical community general may accept use products may develop products accepted results operations suffer many companies targeting diseases conditions competitive products companies could significantly reduce market acceptance products products development programs target number diseases conditions including viral infections fungal infections bacterial infections many commercially available products diseases certain products wellestablished therapies generated substantial sales addition large number companies institutions conducting wellfunded research development activities directed developing treatments diseases products currently market development competitors could make technology products obsolete noncompetitive expect competition treatment diseases increase future new products enter market advanced technologies become available also competing license acquire technology companies competitors potential competitors substantially greater resources resources include superior product development capabilities financial scientific manufacturing marketing managerial human resources competitors may achieve superior patent protection obtain key technology receive regulatory approval achieve product commercialization earlier us significantly greater resources marketing organizations large pharmaceutical companies could hinder ability compete successfully products compete products may develop likely compete products companies currently extensive wellfunded marketing sales operations companies capable devoting significantly greater resources marketing efforts marketing sales efforts may compete successfully efforts companies existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental third party payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies resulted lower average sales prices example majority sales ambisome vistide daunoxome subject reimbursement government agencies resulting significant discounts list price rebate obligations business may adversely affected increase us international pricing pressures pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general us recent years new legislation proposed federal state levels would effect major changes health care system either nationally state level proposals included prescription drug benefit proposals medicare beneficiaries introduced congress although us federal reform legislation states enacted health care reform legislation federal state developments possible although predict exact nature legislative health care reforms results operations could adversely affected reforms europe success tamiflu approved sale viread also depend largely obtaining government reimbursement europe many european countries including united kingdom france patients reluctant pay prescription drugs pocket also expect success products development particularly europe depend ability obtain reimbursement even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis addition many international markets governments control prices prescription pharmaceuticals markets marketing approval receivedin addition many international markets governments control prices prescription pharmaceuticals markets marketing approval received pricing negotiation take another six twelve months longer product sales attempts gain market share introductory pricing programs competitors could require us lower prices countries could adversely affect results operations may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others rights us foreign issued patents filed continue file patent applications us abroad relating technologies risk however patents may issue applications patents sufficient protect technology patent applications confidential least period time sometimes us patent issues result may know competitors filed patent applications technology covered pending applications also certain first invent technology subject patent applications cidecin protected method use patents generally provide level protection composition matter patents competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents patent filings covering forms adefovir dipivoxil china certain asian countries although applications pending various asian countries including china relate various forms formulations adefovir dipivoxil asia major market hbv therapies one potential indications adefovir dipivoxil may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale commercial value product may limited addition patents may provide adequate protection certain countries africa asia including china competitors may file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even successful success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties certain would able obtain alternative technologies required license even obtain technologies licenses certain terms would reasonable fail obtain licenses alternative technologies may unable develop products example may decide use assay method drug screening programs ict pharmaceuticals patents may cover parts program ict pharmaceuticals offered us nonexclusive license patents part industrywide licensing program determined need patents program would need obtain license develop acquire alternative technologies program certain would able obtain license reasonable terms alternative technologies could serve needs future drug development addition use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors number developing countries government officials groups suggested pharmaceutical companies make drugs hiv infection available low cost cases governmental authorities indicated pharmaceutical companies patents might enforceable prevent generic competition major pharmaceutical companies greatly reduced prices hiv drugs certain developing countries certain countries permit enforcement patents sales viread countries could reduced generic competition alternatively governments countries could require grant compulsory licenses allow competitors manufacture sell versions viread countries thereby reducing viread sales could respond governmental concerns reducing prices viread either case results operations would adversely affected manufacturing problems could delay product shipments regulatory approvals vistide adefovir dipivoxil viread rely third parties manufacture bulk drug substance final drug product clinical commercial purposes hoffmannla roche responsible manufacturing tamiflu encounter problems process revenues sales tamiflu could decrease depend third parties perform obligations effectively timely basis third parties fail perform required clinical trials submission products regulatory approval may delayed delays could impair ability deliver commercial products timely basis could impair competitive position hoffmannla roche announced due production problems liquid suspension form tamiflu approved treatment children young one year old currently available expected available flu season expect current production issues material effect earnings manufacture ambisome daunoxome facilities san dimas california formulation manufacturing facilities san dimas california although manufacturing facility ireland performs certain quality control testing labeling packaging use third parties alternate contract suppliers fill freeze dry certain batches product event natural disaster including earthquake equipment failure strike difficulty may unable replace manufacturing capacity timely manner would unable manufacture ambisome daunoxome meet market needs may able obtain materials necessary manufacture products many materials utilize operations made one facility example depend single suppliers high quality amphotericin b daunorubicin hcl distearoylphosphatidylcholine high quality cholesterol used manufacture one liposomal products suppliers key components materials must named new drug application filed fda product significant delays occur qualification new supplier required supplies suppliers interrupted reason could unable ship ambisome viread vistide daunoxome supply products development clinical trials limited experience manufacturing products may able develop adequate manufacturing capacity potential products need develop production technologies use larger scale order conduct clinical trials produce products commercial sale acceptable cost certain able implement developments successfully manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations fda 's current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards addition manufacturing operations subject routine inspections regulatory agencies similar regulations effect countries business may give rise product liability claims covered insurance indemnity agreements testing manufacturing marketing use ambisome viread vistide daunoxome well products development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others successful product liability claim us could require us pay substantial amounts could impair financial condition ability clinically test market products additionally required governmental regulations test products even sold used patients result tests may required may determine recall products already market subsequent testing product recalls may increase potential exposure product liability claims internal research programs efforts obtain rights new products third parties may yield potential products clinical development long term success depends ability either identify either internal research programs potential product candidates may developed new pharmaceutical products obtain new products product candidates licenses third parties significant portion research conduct involve new unproven technologies research programs identify product candidates require substantial technical financial human resources whether candidates identified research programs may appear promising route identifying potential product candidates yet fail yield product candidates clinical development number reasons including research methodology used may successful identifying potential product candidates potential product candidates may study shown unduly harmful side effects characteristics indicate unlikely effective drugs may unable develop larger scale manufacturing methods efficient costeffective capable meeting stringent regulatory standards others may hold intellectual property rights prevent us developing making selling certain products may unable obtain suitable product candidates products third parties number reasons including may unable purchase license compounds terms would allow us make appropriate return product competitors may unwilling assign license product rights us may unable identify suitable products product candidates within areas expertise product candidates acquire may approved regulatory authorities due problems safety effectiveness unable develop suitable potential product candidates internal research programs obtain rights new products third parties future revenue growth suffer use hazardous materials chemicals viruses radioactive compounds exposes us potential liabilities research development involves controlled use hazardous materials chemicals viruses various radioactive compounds although believe safety procedures handling disposing materials comply standards prescribed state federal regulations completely eliminate risk accidental contamination injury materials event accident could held liable significant damages fines item properties corporate headquarters including principal executive offices certain research facilities located foster city california location lease approximately square feet space eight proximately located buildings one subleases covering approximately square feet space group buildings expires december renewal options remaining leases expire march september option renew leases two additional fiveyear periods also occupy facilities san dimas california location lease approximately square feet space houses research development activities manufacturing certain administrative functions leases expire may november two fiveyear renewal options addition lease adjacent warehouse facility square feet space use product distribution administrative functions lease expires april two additional fiveyear extensions addition lease approximately square feet space sales marketing regulatory finance information technology human resource operations europe australia including prepaid year lease square foot manufacturing distribution facility ireland leases various expiration dates believe facilities adequate suitable least current nearterm future needsitem legal proceedings august entered settlement elan corporation successor liposome company inc agreed dismiss legal proceedings involving patents related liposomal formulation amphotericin b settlement agreement elan agreed sue us connection worldwide production sales ambisome gave us rights use patents terms settlement agreement required make payments based ambisome sales next several years also party various legal actions arose ordinary course business believe legal actions significant impact business item submission matters vote securities holders none part ii item market registrant 's common stock related stockholder matters common stock traded nasdaq stock market symbol gild following table sets forth periods indicated high low intraday sale prices per share common stock nasdaq stock market prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february march company implemented twoforone stock splits form stock dividends share per share amounts periods presented restated reflect splits february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception anticipate paying foreseeable future item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data years ended december consolidated statement operations data total revenues total costs expenses loss operations incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net incomeloss amounts per common sharebasic incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net incomeloss per sharebasic shares used per share calculationbasic amounts per common sharediluted incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net incomeloss per sharediluted shares used per share calculationdiluted december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible subordinated debt accumulated deficit total stockholders ' equity completed sale oncology assets related technology osi recorded nonoperating gain million also recorded nonoperating gain million sale percent interest proligo periods prior year ended december restated reflect merger nexstar pharmaceuticals inc july accounted pooling interests gilead adopted statement financial accounting standards nos collectively referred sfas accounting derivative instruments hedging activities first quarter change accounted change accounting principle effective first quarter gilead adopted sec 's staff accounting bulletin sab revenue recognition financial statements change also accounted change accounting principle february march company implemented twoforone stock splits form stock dividends share per share amounts periods presented restated reflect splits cash dividends declared paid company 's common stock item management 's discussion analysis financial condition results operations overview gilead incorporated delaware june independent biopharmaceutical company focused discovery development commercialization antivirals antibacterials antifungals treat lifethreatening infectious diseases multinational company revenues five approved products marketing operations ten countries currently market viread tenofovir disoproxil fumarate treatment hiv infection ambisome amphotericin b liposome injection antifungal agent daunoxome daunorubicin citrate liposome injection drug approved treatment kaposi 's sarcoma vistide cidofovir injection treatment cytomegalovirus cmv retinitis hoffmannla roche inc markets tamiflu oseltamivir phosphate treatment influenza collaborative agreement gilead seeking add existing portfolio products clinical development programs internal discovery programs active product acquisition inlicensing strategy internal discovery activities include identification new molecular targets target screening medicinal chemistry addition currently developing products treat hepatitis b virus bacterial infections also expertise liposomal drug delivery technology use develop drugs safer easier patients tolerate effective december completed sale oncology assets osi pharmaceuticals inc transaction valued million cash osi stock transaction allow us focus continue strengthen core expertise infectious diseases see note consolidated financial statements information february march gilead completed twoforone stock splits effected form stock dividend stockholders record february february respectively accordingly share per share amounts periods presented restated reflect splits year ended december gilead adopted statement financial accounting standards nos collectively referred sfas accounting derivative instruments hedging activities resulted cumulative effect change accounting principle year ended december gilead adopted securities exchange commission 's staff accounting bulletin revenue recognition financial statements also resulting cumulative effect change accounting principle july gilead entered business combination nexstar pharmaceuticals inc nexstar business combination accounted pooling interests historical consolidated financial statements gilead periods prior business combination restated include financial position results operations cash flows nexstar certain prior period amounts reclassified conform current presentationforwardlooking statements risk factors following discussion contains forwardlooking statements involve risks uncertainties gilead 's actual results could differ materially discussed forwardlooking statements factors could cause contribute differences include limited discussed section well caption business including risk factors part forwardlooking statements included document based information currently available gilead assume obligation update forwardlooking statements following discussion read conjunction consolidated financial statements notes included elsewhere report ambisome sales rely sales ambisome significant portion operating income lower priced products compete ambisome product recently approved competes ambisome product fda deemed approvable products developed could compete ambisome future products achieve market acceptance products development become commercially available revenues sales ambisome would likely decrease resulting reduction operating income viread sales future also expect rely sales viread portion operating income number drugs treat hiv infection aids currently sold advanced stages clinical development including products currently sold us among companies significant competitors hivaids market glaxosmithkline bristolmyers squibb hoffmannla roche pfizer merck boehringeringelheim abbott laboratories given broad range competitors depth resources early determine viread achieve significant market penetration particularly use treatment nave patients given data supporting viread 's us approval treatment experienced patient population market acceptance products ability products achieve sustain market acceptance depend number factors including receipt scope regulatory approvals availability public private insurance reimbursement products safety efficacy tolerability cost products products compare competitive products products achieve sustain market acceptance results operations suffer tamiflu new class drugs represent new approach treating preventing flu order tamiflu achieve market acceptance marketing partner roche must change attitudes toward treatment prevention influenza regulatory process us food drug administration foreign agencies could reject limit commercialization products number reasons including disagree results designs clinical trials believe products unacceptable efficacy toxicity tolerability believe products safely efficiently manufactured commercial basis agencies reject limit commercialization products financial results would adversely affected clinical trials required regulatory approval products extremely expensive difficult us accurately predict control amount timing expenses quarter quarter addition regulatory agencies could require us conduct additional unanticipated clinical trials products cost could substantial medicaid governmental reimbursement discount programs business may adversely affected increase pricing pressures us abroad pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general us enacted legislation requires us pay set rebate offer discount products reimbursed medicaid purchased outpatient medicines certain public health service entities certain hospitals sold certain federal purchasers including veterans ' administration recent years new legislation proposed us federal state levels would effect major changes health care system either nationally state level proposals included prescription drug benefit proposals medicare beneficiaries introduced congress although us federal reform legislation states enacted health care reform legislation federal state developments possible although predict exact nature legislative health care reforms results operations would adversely affected national state governments require us sell marketed products lower prices compulsory licensing generic competition number developing countries government officials groups suggested pharmaceutical companies make drugs hiv infection available low cost cases governmental authorities indicated pharmaceutical companies patents might enforceable prevent generic competition major pharmaceutical companies greatly reduced prices hiv drugs certain developing countries certain countries permit enforcement patents sales viread countries could reduced generic competition alternatively governments countries could require grant compulsory licenses allow competitors manufacture sell versions viread countries thereby reducing viread sales could respond governmental concerns reducing prices viread either case results operations would adversely affected collaborations depend collaborations development commercialization certain products revenue including collaboration fujisawa sales ambisome united states canada collaboration roche sales tamiflu worldwide collaboration cubist clinical development cidecin collaborations could fail number reasons including partners devote sufficient resources development commercialization marketing products disputes arise partners also seek additional collaborations collaborations fail unable establish additional collaborations financial results would adversely affected foreign currency fluctuations significant majority product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition past hedge exposure impact fluctuating foreign exchange rates forecasted sales effective january begun use forward contracts hedge percentage forecasted international sales primarily denominated euro currency hedge accounts receivable balances denominated foreign currencies minimizes eliminate exposure currency fluctuations date sale recorded date cash collected additionally mitigate impact currency rate fluctuations cash outflows certain foreign currency denominated raw materials purchases enter foreign exchange forward contracts hedge foreign currencydenominated accounts payable uncertain financial results expect financial results continue fluctuate quarter quarter fluctuations may substantial fluctuations caused many factors beyond control including risk factors listed never profitable fullyear operating basis may never achieve sustain operating profitability december accumulated deficit million critical accounting policies estimatesgilead 's discussion analysis financial condition results operations based upon consolidated financial statements prepared accordance accounting principles generally accepted united states preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosure assets liabilities ongoing basis evaluate estimates including related revenue recognition bad debts inventories accrued clinical preclinical expenses contingencies base estimates historical experience various market specific assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ estimates different assumptions conditions gilead believes following critical accounting policies affect significant judgments estimates used preparation consolidated financial statements record estimated reductions revenue expected returns expired products medicaid reimbursements customer incentives cash discounts prompt payment expected returns marketed drugs generally low shelf life products ranges months viread months ambisome us conditions become competitive markets served drugs circumstances change may take actions increase product return estimates may offer customer incentives action could result incremental reduction future revenue time return estimate changed incentives offered also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments financial condition customers deteriorate resulting impairment ability make payments additional allowances may required write inventory based quality control reviews individual raw material batches generally maintain inventory reserves based estimated obsolescence risk competition primarily shelf life products long however current assumptions future demand competition change actual market conditions less favorable projected management additional inventory writedowns may required record accruals estimated clinical preclinical study costs costs significant component research development expenses management accrues costs clinical studies performed contract research organizations based estimates work upfront costs remaining activity generally straightline basis life individual contract study estimate may may match actual services performed organizations determined patient enrollment levels related activities monitor patient enrollment levels related activity extent possible however management underestimated activity levels associated various studies given point time could record significant research development expenses future periods results operations revenues total revenue million year million year million year included total revenue net product sales royalty income contract revenue including revenue research development rd collaborations net product sales revenue million compared million million revenues primarily derived sales ambisome represented total product sales total product sales total product sales reported sales ambisome million increase ambisome sales million excluding impact decline foreign currencies relative us dollar sales ambisome would increased significant majority gilead 's product sales denominated foreign currencies past hedge exposure impact fluctuating foreign exchange rates forecasted sales effective january begun use forward contracts hedge percentage forecasted international sales primarily denominated euro currency hedge accounts receivable balances denominated foreign currencies reduces exposure currency fluctuations date sale recorded date cash collected sales ambisome million excluding impact decline foreign currencies relative us dollar sales ambisome would increased versus reported sales expected increase competition would expect ambisome sales remain relatively flat versus reported levels assumes foreign currency exchange rates remain consistent levels throughout compared also recognized million viread sales representing total product sales sales daunoxome vistide million million respectively gilead recognized product sales revenue million sales daunoxome million sales vistide daunoxome sales million vistide sales million expect viread sales increase become greater percentage total revenues although predict certainty actual viread sales recorded royalty revenue million compared million million threeyear period significant source royalty revenue sales ambisome united states fujisawa copromotion arrangement gilead fourth quarter began recognizing royalty revenues fujisawa 's sales ambisome month following related product sales occur prior fourth quarter recognized royalty revenue month sales occurred royalty revenue fujisawa million compared million million amount represents royalties months fujisawa sales ambisome also recorded royalty revenue million million related sales tamiflu tamiflu orally administered compound developed treat prevent viral influenza humans gilead codeveloped tamiflu f hoffmannla roche ltd hoffmannla roche inc collectively roche roche owns worldwide commercial rights tamiflu required pay gilead royalty net sales product october fda approved tamiflu treatment influenza adults roche began selling product commercially record royalty revenue roche quarter following quarter related tamiflu sales occur accordingly gilead began recognizing royalties tamiflu first quarter significant declines royalty revenue attributed significantly lower incidence flu season resulting product returns roche expect tamiflu royalties increase somewhat result broader market penetration second half tamiflu approved us prevention adults treatment influenza children approved japan treatment influenza adults february roche filed european regulatory approval tamiflu treatment influenza adults children prevention adolescents adults unclear approval grantedsubstantially remaining net royalty revenue recognized represents royalties sales vistide pharmacia sa pharmacia outside united states future periods royalties sales vistide expected relatively flat decline slightly december securities exchange commission issued staff accounting bulletin sab revenue recognition financial statements among things sab describes sec staff 's position recognition certain nonrefundable upfront fees received connection collaboration agreements previously recognized nonrefundable technology access fees received connection collaboration agreements revenue received collectibility probable technology transferred effective january changed method accounting fees recognize related manufacturing obligation fulfilled straightline basis term related research development collaboration manufacturing supply arrangement appropriate method best matches effort provided believe change accounting principle preferable based guidance provided sab cumulative effect change accounting principle recorded fourth quarter retroactively effective january deferred revenue recognized contract revenue remaining term research development manufacturing supply arrangements appropriate year ended december impact cumulative change accounting principle increase net loss million recognized additional contract revenue million million accordance sab related front fees received prior years million recognized related two collaborative relationships million related initial licensing fee sumitomo million related initial license fee pharmacia million recognized related three collaborative arrangements million sumitomo million pharmacia million related initial licensing fee roche remaining million sab related deferred revenue december results sumitomo pharmacia collaborations expected recognized contract revenue next eleven years remaining deferred revenue related roche initial license fee december total contract revenue million compared million million primary source contract revenue licensing selex process patent estate archemix provided million contract revenue sources contract revenue include million milestone payment roche relating development tamiflu rd collaboration agreement gilead roche million recognized work associated marketing agreements single significant source contract revenue milestone payments roche rd collaboration agreement recorded contract revenue roche million million million contract revenue roche included million milestone payments related roche completing regulatory filings approvals tamiflu us japan million rd expense reimbursements million resulting adoption sab discussed amount included million milestone payments million rd reimbursements rd reimbursements roche decreased compared reimbursements similarly decreased relative tamiflu development efforts ramped roche 's commercialization activities increased december gilead entitled additional milestone payments million upon roche achieving certain developmental regulatory milestones may earn milestone payments roche agreement expect expense reimbursements roche agreement minimal reimbursements approximate actual related costs incurred october entered agreement archemix corporation relating selex technology agreement gave archemix exclusive rights selex process including therapeutic commercial applications extent already licensed preexisting agreements archemix paid us million required pay us million required license agreement university technology corporation paid million payment pay million payment university technology corporation also received warrant purchase shares archemix common stock value material required license agreement university technology corporation transferred warrant university technology corporation march entered agreement eyetech pharmaceuticals inc relating gilead 's proprietary aptamer eye formerly known nx currently early clinical trials eye inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses eye product successfully commercialized eyetech pay us royalties worldwide sales product eyetech also responsible research development costs provided clinical supplies product eyetech march received million upfront licensing fee eyetech april recognized revenue ratably oneyear supply agreement period accordingly million license fee recorded contract revenue remainder recognized revenue first quarter also entitled additional cash payments eyetech million eyetech reaches certain eye development milestones additionally received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors november gilead somalogic inc entered agreement gilead assigned somalogic sole exclusive license certain intellectual property including patents patent applications terms agreement somalogic required pay gilead total million two nonrefundable installments second installment totaled million received november recorded contract revenue upon receipt first installment million received recognized contract revenue november cost expenses cost goods sold million compared million million percentage net product sales cost goods sold connection european product sales price products currency country products sold payment currencies significant majority manufacturing cost us dollars decline value payment currencies relative us dollar negatively impact gross margins since manufacturing costs remain approximately revenues reported us dollars decline gross margin negatively impacted factors discussed product sales section caption revenues excluding impact foreign exchange rates reported sales revenue cost sales percentage net product sales would approximately consistent levels cost sales percentage annual basis range recent years except potential impact unpredictable uncontrollable changes payment currencies relative us dollar expect cost goods sold percentage net product sales remain materially consistent rate future years changes nature mix product sales recent commercial launch viread hiv infection could impact relationshipin research development rd expenses exceeded total costs expenses rd expenses represented approximately total costs expenses major components rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations materials supplies overhead allocations consisting various support facilities related costs research development activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology work clinical development costs include phase ii iii clinical trials well expanded access programs pharmaceutical development costs consist product formulation chemical analysis spent approximately million research million clinical development million pharmaceutical development activities compares spending approximately million research million clinical development million pharmaceutical development activities spending consisted million research million clinical development million pharmaceutical development activities total rd expenses million compared million million million increase spending versus attributable part recognition million million upfront payment million clinical milestone payments cubist european licensing agreement cidecin addition expenses associated phase iii clinical trials expanded access programs viread hiv infection phase iii clinical programs adefovir dipivoxil hbv infection increased approximately million million respectively year based current budgeted programs expect rd expenses approximately million million lower reflecting sale oncology assets osi december decreasing levels activity associated us european expanded access programs viread result expected decrease rd spending percentage total costs expenses expected rd spending levels also increased levels major development projects included viread adefovir dipivoxil hbv infection incurred increased costs programs phase iii clinical trials additionally made upfront payments fourth quarter license two oncology products glaxo smith kline southern research institute rights subsequently assigned osi part sale oncology assets december increases offset significantly lower expenses development adefovir dipivoxil hiv infection program discontinued fourth quarter additionally reduced rd workforce boulder employees upon completing merger nexstar recent industry reports indicate biopharmaceutical product generally takes years average years research develop bring market new prescription medicine us averages generally consistent projects develop internally although recent product development timelines accelerated basis drug development us process includes several steps defined fda process begins filing initial drug application ind successful allows opportunity clinical study potential new medicine clinical development typically involves three phases study phase ii iii generally accounts average seven years drug 's total development time significant costs associated clinical development phase iii trials tend longest largest studies conducted drug development process currently products development phase iii studies successful development products highly uncertain estimation completion dates rd expenses vary significantly product difficult predict complete discussion risks uncertainties associated completing development products see risk factors section item selling general administrative sga expenses million compared million million increase expenses versus primarily due gilead 's increased global marketing efforts expansion sales force support commercial launch viread hiv infection expect sga expenses approximately million million higher levels primarily due increase marketing activities associated launch viread us european union also preparation commercial launch adefovir dipivoxil hbv infection major factor contributing decrease sga expenses levels inclusion million mergerrelated expenses mergerrelated expenses primarily consisted transaction costs including professional fees filing fees printing costs employee severance costs writedown certain nexstar property equipment expected used future operations total employee severance costs million relate termination employees majority boulder colorado facility excluding merger expenses sga expenses essentially flat compared higher general administrative ga expenses offset savings sales marketing expenses increased ga spending included costs implement new upgraded information technology systems legal costs incurred connection new collaboration agreements various corporate projects sales marketing expenses reflect cost savings us elimination second half duplicate positions functions within combined gilead nexstar organization sales marketing expenses included costs expand sales marketing capacity anticipation thenplanned commercial launch adefovir dipivoxil hiv infection discontinued fourth quarter litigation settlement related expenses incurred litigation settlement related expenses million million million reached settlement elan corporation plc elan successor company liposome company companies agreed dismiss legal proceedings involving ambisome gilead 's liposomal formulation amphotericin b terms settlement agreement made initial payment elan million required make additional payments based ambisome sales payments subject certain minimum maximum amounts million accounting charge recorded representing net present value future minimum payments required make record expense quarter based difference future minimum payments amount previously accrued amounts significant expect difference future minimum maximum payments elan material gain sale oncology assets december completed sale oncology assets pipeline clinical stage oncology products related intellectual property well boulder colorado operations including clinical research drug development personnel infrastructure facilities osi pipeline clinical candidates includes nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor closing date received million cash osi common stock valued approximately million company recorded nonoperating gain million fourth quarter result transaction addition recorded income taxes million connection transaction gain sale unconsolidated affiliatein august also sold percent interest proligo llc proligo degussa corporation million cash proligo joint venture gilead skw americas inc focused manufacturing oligonucleotides skw americas subsidiary degussa corporation held remaining percent proligo proceeds net gilead 's investment proligo reflected million gain sale unconsolidated affiliate interest income interest expense recorded interest income million compared million million increase due higher average balances invested funds december received approximately million issuance convertible subordinated notes net debt issuance costs increase due higher interest rates investment portfolio expect interest income materially consistent levels due receipt million cash sale oncology assets december offset lower interest rates portfolio fixed income securities incurred interest expense million compared million million significant increase due full year interest million convertible subordinated notes interest expense consisted primarily interest million convertible notes converted common stock august decrease levels occurred primarily august debt conversion interest expense included full year interest million convertible notes expect interest expense remain consistent expense levels incur full year expense million convertible subordinated notes income taxes provision income taxes million million million respectively periods recorded income tax expense associated income foreign subsidiaries significant increase income tax expense resulted principally gain sale oncology assets osi recorded approximately million federal state alternative minimum taxes equity loss unconsolidated affiliate recorded million equity loss unconsolidated affiliate proligo prior date sale percent interest recorded million equity loss proligo represented percent share proligo 's loss thirteenmonth period ended december fourth quarter proligo changed fiscal yearend december november recorded million equity loss proligo fiscal year ended november cumulative effect change accounting principle year ended december gilead adopted sfas accounting derivative instruments hedging activities resulted cumulative effect change accounting principle million year ended december gilead adopted securities exchange commission 's staff accounting bulletin revenue recognition financial statements resulting cumulative effect change accounting principle million see notes consolidated financial statements discussion liquidity capital resources cash cash equivalents marketable securities totaled million december million december increase million primarily due million cash million osi common stock received part sale oncology assets osi december major sources uses cash included proceeds issuances stock employee stock plans million proceeds million sale interest proligo offset capital expenditures million cash used fund operating activities accounts receivable balance december million compared million december growth primarily due yearoveryear increase net product sales ambisome also initial sales viread us certain countries payments typically slow primarily greece spain portugal italy accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece spain portugal italy totaled approximately million approximately million days past due december past due receivables countries million approximately million days past due date experienced modest losses respect collection accounts receivable believe past due accounts receivable including due customers four countries collectible continually seek improve collection processes ensure fully collect amounts due us based product sales collections timely significant changes working capital included million increase inventory addition accounts payable increased million result increase raw material purchases increased use contract manufacturers substantially growth inventory accounts payable support recent us european launch viread changes working capital include increase accrued liabilities million accrued clinical preclinical expenses increased million primarily due advanced accelerated phase iii clinical trials adefovir dipivoxil hbv infection accrued compensation also increased million december million december principally due expansion sales force support viread launch accrued liabilities increased million consisting principally transaction costs income taxes payable arising sale oncology assets osi noncurrent assets decreased million million december million december decrease due sale percent interest proligo investment proligo december approximately million approximately million date sale decrease partially offset increases resulting million unrecognized portion million license fee payment cubist million valuation warrant purchase stock eyetech recognized accordance sfas million balance resulting cubist payment included noncurrent assets december prior january gilead terminated rights agreement respect preclinical oral formulation daptomycin developed cubist cubist discontinued development oral formulation gilead would entitled receive refund amount cubist made capital expenditures million million million expenditures primarily facilities improvements accommodate growth well laboratory manufacturing equipment million spent approximately research development related expect capital spending decrease somewhat compared levels however percentage allocated research development remain consistent previous year august redeemed convertible subordinated debentures cash price per principal amount debentures outstanding plus accrued interest redemption price provided original debenture indenture upon redemption entire million principal amount debentures outstanding time converted newly issued shares gilead common stock august deferred debt issuance costs million related debentures charged additional paid capital connection conversion debentures common stock december issued million convertible subordinated notes due december private offering notes currently convertible total shares gilead common stock per share conversion price higher common stock price notes ' issuance date notes redeemable whole part option time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes april maintained million unsecured line credit bears interest floating rate major financial institution terms line credit required maintain certain financial ratios limitations ability incur additional debt engage certain significant transactions line credit included foreign exchange facility expired april renewed foreign exchange facility april renew line credit required financial ratios limitations debt transactions foreign exchange facility special purpose entities unconsolidated financial statements also involved nonexchange traded commodity contracts accounted fair value commercial commitments related parties except employee loans contractual obligations form litigation settlement capital operating leases notes payable clinical research organization contracts believe existing capital resources includes fixed income equity securities supplemented net product sales contract royalty revenues adequate satisfy capital needs foreseeable future future capital requirements depend many factors including commercial performance ambisome viread products development receive marketing approval progress research development efforts scope results preclinical studies clinical trials cost timing outcome regulatory reviews rate technological advances determinations commercial potential products development administrative expenses status competitive products establishment manufacturing capacity thirdparty manufacturing arrangements expansion sales marketing capabilities possible geographic expansion establishment additional collaborative relationships companies may future require additional funding could form proceeds equity debt financings additional collaborative agreements corporate partners funding required assure available favorable terms recent accounting pronouncements july financial accounting standards board fasb issued statements financial accounting standards business combinations sfas goodwill intangible assets sfas sfas eliminates poolingofinterests method accounting business combinations except qualifying business combinations initiated prior july sfas clarifies criteria recognize intangible assets separately goodwill requirements sfas effective business combination accounted purchase method completed june sfas goodwill indefinite lived intangible assets longer amortized reviewed annually frequently impairment indicators arise impairment separable intangible assets deemed indefinite life continue amortized useful lives maximum life amortization provisions sfas apply goodwill intangible assets acquired june accounted business combinations purchase method accounting adoption sfas july material impact company 's financial position results operations adoption sfas january material impact company 's financial position results operations august fasb issued sfas accounting impairment disposal longlived assets sfas establishes single accounting model assets disposed sale whether previously held used newly acquired sfas retains presentation discontinued operations income statement broadens presentation include component entity sfas effective fiscal years beginning december interim periods within adoption sfas january material impact company 's financial position results operations market risk disclosuresforeign currency exchange risk operations include manufacturing sales activities united states well sales activities europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes exchange rates us dollar various foreign currencies significant euro british pound australian dollar us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business mitigate impact changes currency exchange rates cash flows foreign currency sales transactions enter foreign exchange forward contracts hedge foreign currencydenominated accounts receivable additionally mitigate impact currency rate fluctuations cash outflows certain foreign currencydenominated raw materials purchases enter foreign exchange forward contracts hedge foreign currencydenominated accounts payable following table summarizes notional amounts average currency exchange rates fair values open foreign exchange forward contracts december contracts maturities one year less one exception one hedge contract intended hedge raw materials purchases first quarter notional amount million insignificant fair value december maturity months average rates stated terms amount foreign currency per us dollar fair values represent estimated settlement amounts december notional amounts fair values us thousands fair value currency notional amount average rate december australian dollar british pound danish krone euro norwegian krone swiss franc significant majority product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition past hedge exposure impact fluctuating foreign exchange rates forecasted sales effective january begun use forward contracts hedge percentage forecasted international sales primarily denominated euro currency interest rate risk portfolio availableforsale investment securities fixedrate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestbearing assets fixedrate liabilities december dollars thousands years ending december fair value december thereafter total assets availableforsale securities average interest rate liabilities minimum litigation settlement including current portion discount rate longterm obligations including current portion average interest rate convertible subordinated debentures interest rate longterm obligations consist capital leases operating leases net noncancelable subleases debt secured property plant equipment interest portion payments due included item quantitative qualitative disclosures market risk quantitative qualitative disclosure market risk included caption market risk disclosures item item financial statements supplementary data financial statements required item set forth beginning report item changes disagreements accountants accounting financial disclosure applicable part iii item directors executive officers registrant information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting proxy statement headings nominees executive officers compliance section securities exchange act item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee report item security ownership certain beneficial owners management information required item incorporated reference section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions information required item incorporated reference sections proxy statement headings compensation committee interlocks insider participation certain transactions executive compensation part iv item exhibits financial statement schedules reports form k following documents filed part schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc dated november amended restated certificate incorporation registrant amended bylaws registrant amended restated march reference made exhibit exhibit amended restated rights agreement dated october registrant chasemellon shareholder services llc agreement plan merger dated february among registrant gazelle acquisition sub inc nexstar pharmaceuticals inc indenture dated december registrant chase manhattan bank trust company national association including therein forms notes registration rights agreement dated december registrant jp morgan securities inc chase securities inc lehman brothers inc morgan stanley co incorporated form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees registrant 's incentive stock option plan related agreements registrant 's supplemental stock option plan related agreements registrant 's employee stock purchase plan amended march registrant 's stock option plan amended restated april form nonqualified stock option issued certain executive officers directors vintage park research development net lease registrant vintage park associates dated march premises located b lakeside drive foster city california related addendum exhibits amendments letter agreement dated september registrant iocbrega exhibits certain confidential information omitted vintage park research development net lease registrant vintage park associates dated september premises located lakeside drive foster city california related exhibits amendment agreement dated october registrant iocbrega related license agreements exhibits certain confidential information omitted amendment agreement dated december registrant iocbrega loan agreement dated october among registrant mark l perry melanie p pea registrant 's nonemployee directors ' stock option plan amended january related form stock option grant vintage park research development lease registrant wcb sixteen limited partnership dated june premises located lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limited partnership dated june premises located lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limited partnership dated june premises located b lakeside drive foster city california license supply agreement registrant pharmacia upjohn sa dated august certain confidential information omitted development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc dated september certain confidential information omitted amendment vintage park research development lease registrant spieker properties lp dated august premises located lakeside drive foster city california nexstar pharmaceuticals inc 's incentive stock plan adopted february amended nexstar pharmaceuticals inc 's director option plan adopted july vestar inc stock option plan lease dated march vestar inc majestic realty co patrician associates inc amendment thereto amendment thereto dated june third amendment dated january majestic realty co patrician associates inc registrant lease dated march vestar inc majestic realty co patrician associates inc assignment royalty agreement dated december effective june vestar inc city hope national medicalcenter license agreement effective august vestar inc regents university california agreement fujisawa usa inc vestar inc dated august amendment thereto dated may amendment agreement fujisawa usa inc vestar inc dated april fujisawa usa inc vestar inc certain confidential information omitted amendment agreement fujisawa usa inc registrant dated march agreement fujisawa usa inc vestar inc dated august lease dated april vestar inc majestic realty co patrician associates inc first amendment lease dated april majestic realty co patrician associates inc vestar inc amending lease dated april majestic realty co patrician associates inc vestar inc license distribution agreement dated september sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc certain confidential information omitted settlement agreement dated august among nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omitted amendment dated april sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc license distribution agreement dated september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc deferred compensation plan subsidiaries registrant consent ernst young llp independent auditors consent pricewaterhousecoopers llp independent auditors power attorney reference made signature filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's current report form k filed october incorporated herein reference filed exhibit registrant 's registration statement form amended incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's annual report fiscal year ended march incorporated herein referencefiled exhibit registrant 's annual report fiscal year ended march incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's current report form k filed march incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed march exhibit nexstar pharmaceuticals inc 's registration statement form file incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarter ended june incorporated herein reference filed exhibit registrant 's year ended december incorporated herein reference filed exhibit registrant 's year ended december incorporated herein reference filed exhibit registrant 's registration statement form amended incorporated herein reference filed exhibit registrant 's year ended december incorporated herein reference filed exhibit registrant 's current report form k filed january incorporated herein reference b reports form k registrant file reports form k fourth quarter january registrant filed current report form k relating completion sale oncology assets pipeline clinical stage oncology products related intellectual property well boulder colorado operations including clinical research drug development personnel infrastructure facilities osi pharmaceuticals inc form k includes unaudited pro forma condensed consolidated balance sheet september presented transaction occurred date unaudited pro forma condensed consolidated statements operations year ended december nine months ended september presented transaction occurred january january respectively gilead sciences inc consolidated financial statements years ended december contents report independent auditors report independent accountants audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders ' equity consolidated statements cash flows notes consolidated financial statements report ernst young llp independent auditors board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc subsidiaries december related consolidated statements operations stockholders ' equity cash flows three years period ended december audits also included financial statement schedule listed item annual report financial statements schedule responsibility management gilead sciences inc responsibility express opinion financial statements schedule based audits audit financial statements proligo llc limited liability company investment reflected accompanying consolidated financial statements using equity method accounting investment proligo llc represents consolidated total assets december company'sequity net loss proligo llc respectively financial statements proligo llc audited auditors whose report furnished us insofar opinion consolidated financial statements relates data included proligo llc based solely report conducted audits accordance auditing standards generally accepted united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits report auditors provide reasonable basis opinion opinion based audits report auditors consolidated financial statements referred present fairly material respects consolidated financial position gilead sciences inc subsidiaries december consolidated results operations cash flows three years period ended december conformity accounting principles generally accepted united states also opinion financial statement schedule referred considered relation basic financial statements taken whole presents fairly material respects information set forth therein discussed notes consolidated financial statements effective january company changed method accounting derivative instruments hedging activities effective january changed method accounting nonrefundable upfront fees received connection collaboration agreements ernst young llp palo alto california january except paragraph titled stock split note date march report independent accountants board directors members proligo llc opinion accompanying consolidated balance sheets related consolidated statements operations members ' equity cash flows present fairly material respects financial position proligo llc subsidiaries december november results operations cash flows thirteenmonths ended december year ended november period august november respectively conformity accounting principles generally accepted united states america financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecoopers llp broomfield colorado january gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents marketable securities accounts receivable net allowance doubtful accounts inventories prepaid expenses total current assets property plant equipment net noncurrent assets liabilities stockholders ' equity current liabilities accounts payable accrued clinical preclinical expenses accrued compensation employee benefits accrued liabilities deferred revenue longterm obligations due within one year total current liabilities longterm deferred revenue accrued litigation settlement expenses due one year longterm obligations due one year convertible subordinated debt commitments contingencies see accompanying notes stockholders ' equity preferred stock par value per share issuable series shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december shares issued outstanding december additional paidin capital accumulated comprehensive income loss deferred compensation accumulated deficit total stockholders ' equity see accompanying notes gilead sciences inc consolidated statements operations thousands except per share amounts year ended december revenues product sales net royalty revenue net contract revenue contract revenuesab total revenues costs expenses cost goods sold research development selling general administrative total costs expenses loss operations gain sale oncology assets gain sale unconsolidated affiliate interest income interest expense income loss provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle provision income taxes equity loss unconsolidated affiliate income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic shares used per share calculationbasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted shares used per share calculationdiluted see accompanying notes gilead sciences inc consolidated statement stockholders ' equity thousands accumulated common stock additional comprehensive total preferred paidin income deferred accumulated stockholders ' stock shares amount capital loss compensation deficit equity balance january net loss unrealized loss available forsale securities net foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercises net warrant exercises net conversion shares preferred stock conversion convertible subordinated debentures amortization deferred compensation compensatory stock transactions balance december net loss unrealized gain available forsale securities net foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercises net warrant exercises net conversion convertible subordinated debentures amortization deferred compensation compensatory stock transactions balance december net income unrealized gain available forsale securities net foreign currency translation adjustment unrealized gain cash flow hedges net comprehensive income employee stock purchase plan option exercises net tax benefits employee stock plans amortization deferred compensation compensatory stock transactions balance december see accompanying notes gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income loss adjustments reconcile net income loss net cash used operating activities depreciation amortization net effect change accounting principle compensation expense stock option transactions gain sale oncology assets net securities received gain sale unconsolidated affiliate equity loss unconsolidated affiliate litigation settlement charges net provision doubtful accounts tax benefits employee stock plans net unrealized gain loss foreign currency transactions changes operating assets liabilities accounts receivable inventories prepaid expenses assets longterm prepaid royalties accounts payable accrued liabilities deferred revenue excluding net effect change accounting principle net cash used operating activities investing activities purchases marketable securities sales marketable securities maturities marketable securities capital expenditures proceeds sale oncology assets proceeds sale unconsolidated affiliate investment unconsolidated affiliate net cash provided used investing activities financing activities proceeds issuances common stock repayments longterm debt proceeds issuance convertible subordinated notes net issuance costs net cash provided financing activities effect exchange rate changes cash net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash flow information interest paid income taxes paid noncash investing financing activities osi common stock received upon sale oncology assets common stock issued upon conversion debentures reclassification deferred debt issuance costs additional paidin capital upon conversion subordinated debentures see accompanying notes gilead sciences inc notes consolidated financial statements december organization summary significant accounting policies overview gilead incorporated delaware june independent biopharmaceutical company focused discovery development commercialization antivirals antibacterials antifungals treat lifethreatening infectious diseases multinational company revenues five approved products operations ten countries currently market viread treatment hiv infection ambisome antifungal agent daunoxome drug approved treatment kaposi 's sarcoma vistide treatment cytomegalovirus cmv retinitis hoffmannla roche inc markets tamiflu treatment influenza collaborative agreement gilead seeking add existing portfolio products clinical development programs internal discovery programs active product acquisition inlicensing strategy internal discovery activities include identification new molecular targets target screening medicinal chemistry addition currently developing products treat hepatitis b virus bacterial infections also expertise liposomal drug delivery technology use develop drugs safer easier patients tolerate effective fully described note july gilead entered business combination merger nexstar pharmaceuticals inc nexstar business combination accounted pooling interests historical consolidated financial statements gilead years prior business combination restated include financial position results operations cash flows nexstar material adjustments necessary conform accounting policies two companies costs merger charged operations accompanying consolidated financial statements include accounts company wholly majorityowned subsidiaries significant intercompany transactions eliminated certain prior period amounts reclassified consistent current presentation stock split february march gilead completed twoforone stock splits effected form stock dividend stockholders record february february respectively accordingly share per share amounts periods presented restated reflect splits changes accounting principles gilead adopted statement financial accounting standards sfas nos collectively referred sfas accounting derivative instruments hedging activities first quarter change accounted change accounting principle see note derivative financial instruments effective first quarter gilead adopted sec 's staff accounting bulletin sab revenue recognition financial statements change also accounted change accounting principle see note critical accounting policies estimates preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosure assets liabilities ongoing basis evaluate estimates including related revenue recognition bad debts inventories accrued clinical preclinical expenses contingencies base estimates historical experience various market specific assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates different assumptions conditions revenue recognition product sales revenue recognized upon passage legal title inventory satisfaction company 's performance obligations company provide customers general right product return however company accept returns product expired deemed damaged defective delivered provisions made doubtful accounts estimated product returns cash discounts government discounts rebates contract revenue research development recorded earned based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier payments received collection assured revenue nonrefundable upfront license fees continue involvement development collaboration obligation supply product isrecognized manufacturing obligation fulfilled ratably development period period manufacturing obligation appropriate revenue associated substantive performance milestones recognized based upon achievement milestones defined respective agreements revenue research development cost reimbursement contracts recognized related costs incurred advance payments received excess amounts earned classified deferred revenue royalty revenue sales ambisome recognized month following corresponding sales occur royalty revenue sales vistide tamiflu recognized received quarter following quarter corresponding sales occur research development costs major components rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations materials supplies overhead allocations consisting various administrative facilities related costs research development activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology work clinical development costs include phase ii iii clinical trials well expanded access programs pharmaceutical development costs consist product formulation chemical analysis record accruals estimated clinical preclinical study costs costs significant component research development expenses management accrues costs clinical studies performed contract research organizations based estimates work upfront costs remaining activity generally straightline basis life individual contract study estimate may may match actual services performed organizations determined patient enrollment levels related activities monitor patient enrollment levels related activity extent possible however management underestimated activity levels associated various studies given point time could record significant research development expenses future periods advertising expenses company expenses costs advertising including promotional expenses incurred advertising expenses million million million stockbased compensation accordance provisions sfas accounting stockbased compensation company elected follow accounting principles board opinion apb accounting stock issued employees interpretation fin accounting certain transactions involving stock compensationan interpretation apb opinion accounting employee stock option plans apb exercise price company 's employee director stock options equals exceeds fair value underlying stock date grant compensation expense recognized see note pro forma disclosures stockbased compensation pursuant sfas per share computations basic net income per common share computed based weighted average number common shares outstanding period diluted net income per common share includes effects approximately million stock options warrants include effect million convertible notes would convert approximately million shares effect antidilutive periods presented prior basic diluted loss per common share computed based weighted average number common shares outstanding period convertible notes stock options warrants well convertible debentures previously outstanding excluded computation diluted loss per share effect antidilutive periods presented prior share per share amounts periods presented restated reflect stock splits february march cash cash equivalents company considers highly liquid investments insignificant interest rate risk remaining maturity three months less purchase date cash equivalents gilead may enter overnight repurchase agreements purchases securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents company 's investment policy may enter repurchase agreements repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold gilead marketable securities management determines appropriate classification marketable securities time purchase reevaluates designation balance sheet date company 's marketable securities classified availableforsale carried estimated fair values reported either cash equivalents marketable securities december cash cash equivalents include million securities designated availableforsale million december unrealized gains losses availableforsale securities excluded earnings reported separate component stockholders ' equity interest income includes interest dividends amortization purchase premiums discounts realized gains losses sales securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value determine decline fair value investment accounting basis otherthantemporary reduce carrying value securities hold record loss amount decline reductions required past three years concentrations credit risk gilead subject credit risk portfolio cash equivalents marketable securities policy company limits amounts invested securities maturity industry group investment type issuer except securities issued us government gilead exposed significant concentrations credit risk financial instruments however hold shares osi common stock result sale oncology assets osi seenote shares fair value million december represent entire portfolio marketable equity securities goals company 's investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return gilead also subject credit risk accounts receivable related product sales majority company 's trade accounts receivable arises sales ambisome primarily sales european subsidiaries export sales distributors europe certain countries payments typically slow primarily greece spain portugal italy accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding date experienced modest losses respect collection accounts receivable believe past due accounts receivable including due customers four countries collectible continually seek improve collection processes ensure fully collect amounts due us based product sales collections timely perform credit evaluations customers ' financial condition generally required collateral date experienced modest credit losses respect accounts receivable inventories inventories recorded lower cost market cost determined firstin firstout basis management periodically reviews composition inventory order identify obsolete slowmoving otherwise unsaleable items items observed alternate uses inventory company record writedown net realizable value period units identified impaired historically inventory writedowns insignificant consistent management 's expectations property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straight line method estimated useful lives follows description estimated useful life years building leasehold improvements laboratory manufacturing equipment office computer equipment office computer equipment includes capitalized computer software company 's capitalized software purchased company internally developed computer software leasehold improvements capitalized leased equipment amortized shorter lease term item 's useful life noncurrent assets noncurrent assets december includes million prepaid royalties paid institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega discussed iocbrega caption note also included noncurrent assets december deferred debt issuance costs million net accumulated amortization million related million subordinated convertible notes gilead issued december longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment us food drug administration another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated incomeproducing asset indication impairment company confirm comparing estimated future cash flows expected result use asset eventual disposition carrying amount asset estimating future cash flows assets grouped lowest level identifiable cash flows largely independent cash flows generated asset groups sum expected future cash flows undiscounted without interest changes less carrying amount asset impairment loss measured excess carrying value asset fair value recognized cash flow estimates used calculations based management 's best estimates using appropriate customary assumptions projections time current accrued liabilities december december accrued liabilities included million accrued litigation settlement costs see legal proceedings discussion note foreign currency translation transactions contracts adjustments resulting translating financial statements company 's foreign subsidiaries us dollars excluded determination net income accumulated separate component stockholders ' equity net foreign exchange transaction losses reported selling general administrative expense consolidated statements operations losses million million million company hedges certain foreign currency exposures related outstanding trade accounts receivable firmly committed purchase transactions foreign exchange forward contracts general contracts expose company market risk gains losses contracts offset gains losses transactions hedged company 's exposure credit risk contracts function changes interest currency exchange rates therefore varies time gilead limits risk counterparties contracts may unable perform transacting major us banks company also limits risk loss entering contracts provide net settlement maturity therefore company 's overall risk loss event counterparty default limited amount unrecognized unrealized gains outstanding contracts ie contracts positive fair value date default company enter speculative foreign currency transactions write options accounting hedges accounts receivable company 's aggregate net foreign currency transaction gain loss reported selling general administrative expense prior adoption sfas january company recognized net unrealized gain loss outstanding forward contracts based difference contract exchange rate market exchange rate balance sheet date respect hedges firmly committed purchase transactions unrealized gains losses underlying forward contracts deferred reported component related transaction period occurred december company net unrealized losses open foreign exchange forward contracts million company forward exchange contracts outstanding million december million december contracts maturities one year less one exception one hedge contract intended hedge raw materials purchases first quarter notional amount million fair value december maturity months company presently hedge net investment foreign subsidiaries effective january begun use forward contracts hedge percentage forecasted international sales primarily denominated euro currency see note discussion derivative financial instruments adoption sfas fair value financial instruments company 's financial instruments consist principally cash cash equivalents marketable securities accounts receivable certain noncurrent assets forward foreign exchange contracts accounts payable longterm obligations convertible subordinated notes cash cash equivalents marketable securities forward foreign exchange contracts hedge accounts receivable reported respective fair values balance sheet forward foreign exchange contracts hedge firmly committed purchases recorded fair value net related deferred gain loss resulting reported net balance zero management believes remaining financial instruments exception convertible subordinated notes reported balance sheet amounts approximate current fair values fair value convertible subordinated notes december million fair value december million carrying value end period million fair value december determined obtaining quote market maker notes fair value december obtained multiplying number shares notes converted per share market price gilead 's common stock december plus accrued interest recent accounting pronouncements july financial accounting standards board fasb issued sfas business combinations sfas goodwill intangible assets sfas sfas eliminates poolingofinterests method accounting business combinations except qualifying business combinations initiated prior july sfas clarifies criteria recognize intangible assets separately goodwill requirements sfas effective business combination accounted purchase method completed june sfas goodwill indefinite lived intangible assets longer amortized reviewed annually frequently impairment indicators arise impairment separable intangible assets deemed indefinite life continue amortized useful lives maximum life amortization provisions sfas apply goodwill intangible assets acquired june gilead accounted business combinations purchase method accounting adoption sfas july material impact company 's financial position results operations adoption sfas january material impact company 's financial position results operations august fasb issued sfas accounting impairment disposal longlived assets sfas establishes single accounting model assets disposed sale whether previously held used newly acquired sfas retains presentation discontinued operations income statement broadens presentation include component entity sfas effective fiscal years beginning december interim periods within adoption sfas january material impact company 's financial position results operations cumulative change accounting principle december securities exchange commission issued staff accounting bulletin sab revenue recognition financial statements among things sab describes sec staff 's position recognition certain nonrefundable upfront fees received connection collaboration agreements company previously recognized nonrefundable technology access fees received connection collaboration agreements revenue received collectibility probable technology transferred effective january gilead changed method accounting fees recognize related manufacturing obligation fulfilled straightline basis term related research development collaboration manufacturing supply arrangement appropriate method best matches effort provided management believes change accounting principle preferable based guidance provided sab cumulative effect change accounting principle recorded fourth quarter retroactively effective january deferred revenue recognized contract revenue remaining term research development manufacturing supply arrangements appropriate year ended december net impact change accounting principle increase net loss million per share loss consists million cumulative effect change ofjanuary net million related deferred revenue recognized contract revenue year additional million contract revenue recognized remainder million related deferred revenue balance december expected recognized revenue fiscal years derivative financial instruments january gilead adopted sfas standard requires gilead recognize derivatives either assets liabilities measured fair value derivative designated meets definition fair value hedge changes fair value derivative hedged item attributable hedged risk recognized earnings derivative designated meets definition cash flow hedge effective portions changes fair value derivative recorded comprehensive income recognized income statement hedged item affects earnings ineffective portions changes fair value cash flow hedges recognized earnings immediately sfas also classifies warrants purchase capital stock nonpublic company include net exercise feature derivatives upon adoption recorded balance sheet fair value offsetting amount recorded results operations subsequent changes fair value warrants required remeasured balance sheet date changes fair value warrants recorded results operations gilead sells product purchases raw materials internationally us dollars local currency forecasted actual foreign currency risks hedged forward currency contracts generally maturities months less derivative instruments employed eliminate minimize certain foreign currency exposures confidently identified quantified forward contracts hedging nonfunctional currency assets liabilities sfas designated hedges changes fair value recognized immediately earnings accordance sfas hedges related anticipated foreign currency purchases raw materials designated documented inception respective hedge designated cash flow hedges evaluated effectiveness quarterly terms forward contract underlying transaction matched inception forward contract effectiveness calculated comparing fair value contract change forward value underlying hedged item effective portion gain loss derivative instrument reported component comprehensive income stockholders ' equity reclassified earnings period periods hedged transaction affects earnings upon adoption sfas recorded fair value million related forward contracts previously reflected balance sheet recognized cumulative transition adjustment comprehensive income million effective component hedge substantially values reported comprehensive income december reclassified earnings within months residual changes fair value instruments ineffectiveness recognized immediately selling general administrative expense ineffectiveness significant gilead holds warrants purchase stock two nonpublic companies warrants net exercise features sfas classified derivative instruments upon adoption gilead recorded fair value one warrants offsetting adjustment cumulative change accounting principle year ended million loss hedging contracts recognized income statement million reduction fair value derivatives recognized comprehensive income december fair value derivatives recognized comprehensive income material sale oncology assets december gilead completed sale oncology assets pipeline clinical candidates oncology related intellectual property well boulder colorado operations including clinical research drug development operations infrastructure facilities osi pharmaceuticals inc osi three clinical development candidates sold osi nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor consideration gilead received million cash shares osi common stock valued approximately million december number shares issued gilead determined dividing million average closing sale price osi common stock days preceding december also entitled additional payments osi million either cash combination cash osi common stock osi reaches certain development milestones nx advanced oncology product candidates sold osi based upon december net book value oncology assets sold million transaction costs million million related acceleration approximately options purchase gilead common stock company realized pretax gain million fourth quarter carrying value transferred assets relates primarily certain property equipment osi assumed gilead 's oncologyrelated clinical preclinical obligations well various lease obligations related manufacturing agreement produce osi liposomal formulations nx gs l two liposomal products sold osi manufacturing facility san dimas ca acquisition nexstar july company acquired outstanding common stock nexstar pharmaceuticals agreement dated february result nexstar became wholly owned subsidiary gilead connection merger gilead issued total million shares gilead common stock nexstar 's stockholders consideration shares common stock nexstar addition holders options warrants outstanding time merger purchase aggregate approximately million shares nexstar common stock would receive upon exercise options warrants fraction share gilead common stock holders million principal amount convertible subordinated debentures nexstar received right convert debentures approximately million shares gilead common stock merger qualified taxfree reorganization accounted pooling interests table presents separate results operations gilead nexstar periods prior merger combined results merger thousands mergerrelated gilead nexstar adjustments total year ended december revenues net income loss mergerrelated costsb adjustment required conform accounting policy nexstar 's policy capitalize certain patent trademark costs gilead 's policy charge items selling general administrative expense period incurred accompanying financial statements restated periods patent trademark costs expensed incurred result merger nexstar company incurred mergerrelated costs consisting transaction costs primarily professional fees filing fees printing costs related charges employee severance costs writedown certain nexstar assets would used continuing operations following table shows details mergerrelated costs accruals december thousands charged expense december december utilized accrual balance merger transaction costs employee severance writedown nexstar assets na na total employees severance costs accrued terminated december substantially remaining accrued severance costs paid former employees december merger transaction costs utilized december availableforsale securities following summary availableforsale securities estimated fair values availableforsale securities based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december us treasury securities obligations us government agencies certificates deposit corporate debt securities corporate equity securities assetbacked securities debt securities total december us treasury securities obligations us government agencies certificates deposit corporate debt securities assetbacked securities debt securities total debt securities consist primarily money market funds following table presents certain information related sales availableforsales securities thousands year ended december proceeds sales gross realized gains sales gross realized losses sales december million company 's portfolio marketable securities excluding million assetbacked securities million equity securities contractual maturity less one year million portfolio contractual maturity greater one year less three years none estimated maturities company 's assetbacked securities exceed three years marketable equity securities consisting osi common stock expected available sale first half collaborative arrangements contractscubist pharmaceuticals january gilead entered agreement cubist pharmaceuticals inc cubist relating cubist 's antibacterial compound daptomycin including cidecin intravenous formulation compound currently phase iii clinical trials treatment bacterial infections terms agreement gilead paid cubist upfront license fee million received exclusive commercial rights compound sixteen european countries gilead 's territory well right develop compound commercialization territory research development expense charged million million payment million balance included noncurrent assets december prior january gilead terminated rights agreement respect preclinical oral formulation daptomycin developed cubist cubist discontinued development oral formulation gilead would entitled receive refund amount cubist subsequent january refundable amount reduced ratably monthly basis fouryear period amortized research development expense cubist continue responsible worldwide clinical development cidecin preclinical oral formulation gilead responsible regulatory filings marketing selling product within gilead 's territory gilead also agreed make additional payments cubist million certain clinical regulatory milestones related cidecin oral formulation reached three milestones met gilead paid million related milestones payments recorded research development expense additionally cidecin successfully commercialized gilead 's territory gilead pay cubist royalty net sales product archemix october entered agreement archemix corporation relating selex technology agreement gave archemix exclusive rights selex process including therapeutic commercial applications extent already licensed preexisting agreements archemix paid us million required pay us million required license agreement university technology corporation paid million payment pay million payment university technology corporation also received warrant purchase shares archemix common stock value material required license agreement university technology corporation transferred warrant university technology corporation eyetech march gilead entered agreement eyetech pharmaceuticals inc relating gilead 's proprietary aptamer eye currently early clinical trials eye inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses eye product successfully commercialized eyetech pay gilead royalties worldwide sales product eyetech also responsible research development costs gilead provide clinical supplies product eyetech march gilead received million upfront licensing fee eyetech april recognized revenue ratably oneyear supply agreement period accordingly million license fee recorded contract revenue agreement remainder license fee recognized revenue gilead also entitled additional cash payments eyetech million eyetech reaches certain eye development milestones additionally gilead received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors see note description accounting treatment warrant fujisawa company 's rights market ambisome subject agreement company fujisawa healthcare inc successor fujisawa usa inc fujisawa terms fujisawa agreement amended fujisawa company copromote ambisome united states fujisawa sole marketing rights ambisome canada company exclusive marketing rights ambisome rest world provided company pays royalties fujisawa connection sales significant asian markets including japan connection us sales fujisawa purchases ambisome company cost sales canada fujisawa purchases ambisome cost plus specified percentage fujisawa collects payments sale ambisome united states canada company receives fujisawa 's gross profits sale ambisome united states gross profits include deduction cost goods sold giving company current effective royalty rate approximately fujisawa 's net sales ambisome united states connection agreement company fujisawa gilead recorded royalty revenue million million million sumitomo september company sumitomo pharmaceuticals co ltd sumitomo entered agreement sumitomo license pursuant sumitomo agreed develop market ambisome japan terms sumitomo license sumitomo paid company initial million licensing fee less withholding taxes million october million milestone payment less withholding taxes million march sumitomo also required make additional payments company certain clinical commercial milestones met pay company royalties japanese ambisome sales sumitomo license gilead obligated provide certain quantity ambisome sumitomo charge ambisome yet approved marketing japan subsequent cumulative effect change accounting principle recorded effective first quarter resulting adoption sab gilead recognizing initial license fee remaining free supply arrangement period currently expected next five years net impact change accounting principle sumitomo license increase net loss million cumulative effect change accounting principle charge million contract revenue million related initial licensing fee sumitomo recognized contract revenue million recognized contract revenue remaining million related deferred revenue december recognized contract revenue remaining free supply obligation period hoffmannla roche september gilead entered collaboration agreement f hoffmannla roche ltd hoffmannla roche inc collectively roche develop commercialize therapies treat prevent viral influenza roche agreement roche agreement roche received exclusive worldwide rights togilead 's proprietary influenza neuraminidase inhibitors prior roche made license fee developmental milestone payments totaling million gilead recognized total million additional milestone payments due commencement certain clinical trials japan filing application market tamiflu european union filing subsequent approval market tamiflu united states gilead recognized million contract revenue milestone payments roche related tamiflu milestones achieved year milestones included filing regulatory approval japan treatment influenza japanese approval application filing us regulatory approval prevention influenza receipt approval us recognized million milestone payment filing application market tamiflu prophylaxis european union subsequent cumulative effect change accounting principle recorded effective first quarter resulting adoption sab gilead recognized initial license fee remaining research development period ended first quarter net impact change accounting initial license fee zero cumulative effect change accounting principle related roche license fee million charge results operations offset additional contract revenue million also recognized first quarter remaining deferred revenue related roche initial license fee december december gilead entitled additional cash payments roche million upon roche achieving additional developmental regulatory milestones addition roche required pay gilead royalties net product sales gilead began receiving royalties roche 's sales tamiflu first quarter recorded total million tamiflu royalties year million royalties tamiflu royalties recorded company recognizes royalty revenue roche quarter following quarter related tamiflu sales occur roche agreement roche also reimburses company related rd costs program funding costs quarterly generally advance based annual budget reimbursements included contract revenue company incurs related rd costs amounts incurred company excess amounts funded may also reimbursed subject roche 's approval event revenue recognized approval obtained conversely amounts funded roche exceed company 's related rd costs company may required repay excess funding roche company recorded contract revenue rd reimbursements related roche agreement approximately million million million rd costs related roche agreement approximate reimbursement revenue year presented included rd expenses pharmacia august company pharmacia corporation pharmacia entered license supply agreement pharmacia agreement market vistide countries outside united states terms pharmacia agreement pharmacia paid gilead initial license fee million subsequent cumulative effect change accounting principle recorded effective first quarter gilead recognizing initial license fee straightline basis supply arrangement period sixteen years agreement date net impact change accounting principle pharmacia agreement increase net loss million cumulative effect change accounting principle related initial license fee pharmacia million charge results operations additional contract revenue million recognized subsequent accounting change remaining million related deferred revenue expected recognized straightline basis contract revenue remaining supply period twelve years beginning january second quarter vistide approved marketing european union european commission triggered additional cash milestone payment million pharmacia company also result achieving milestone second quarter pharmacia purchased shares series b convertible preferred stock approximately million per share preferred stock automatically converted shares common stock additional information preferred stock see note terms pharmacia agreement related agreements covering expanded access programs vistide outside united states gilead responsible maintaining cidofovir patent portfolio supplying pharmacia bulk cidofovir used manufacture finished vistide product gilead entitled receive royalty based upon pharmacia 's sales vistide gilead receives portion royalty upon shipping either bulk drug substance vistide pharmacia remainder upon pharmacia 's sale vistide third parties royalties gilead receives product sold third parties recorded deferred revenue thirdparty sales occur december company recorded balance sheet approximately million deferred revenue million december company recognized royalty revenue sales vistide outside united states pharmacia million million million somalogic november gilead somalogic inc somalogic entered agreement whereby gilead assigned somalogic sole exclusive license certain intellectual property related selex process diagnostic purposes including patents patent applications terms agreement somalogic required pay gilead total million two nonrefundable installments first million paid november included contract revenue year ended december remaining million reported deferred revenue december received recorded contract revenue gilead ongoing research funding obligations agreement schering ag company entered collaborative research agreement schering research agreement license agreement schering license agreement schering ag schering research agreement schering ag funded research gilead discovery development aptamers vivo diagnostic agents level funding agreement varied annually high million million received recorded contract revenue schering research agreement expired company expect receive additional payments thereunder schering license agreement schering ag right develop commercialize aptamers vivo diagnostic agents radiotherapeutics discovered developed schering research agreement schering ag required make milestone royalty payments company upon commercialization sale products developed collaboration company milestone payments one product total million triggered filing investigational new drug application initiation phase iii clinical trials filing nda approval product commercial sale schering license agreement still effect december permits company develop commercialize aptamers discovered schering research agreement outside field vivo diagnostic agents radiotherapeutics subject royalty payments schering agglaxosmithkline december gilead entered agreement glaxo wellcome glaxosmithkline glaxo giving gilead rights gs l novel antitumor compound gilead developing gs l liposome evaluating preclinical studies agreement gilead exclusive worldwide rights develop commercialize gs l indications malaria gilead paid glaxo upfront fee included rd expense december compound assigned osi part sale oncology assets may gilead entered threepart collaboration glaxo glaxo received nonexclusive right use gilead 's proprietary selex process target validation b gilead received exclusive rights subject glaxo 's right elect participate activities develop commercialize nx liposomal formulation glaxo 's proprietary topoisomerase inhibitor lurtotecan c glaxo acquired shares gilead common stock million private offering december collaboration license agreement modified revised terms agreement glaxo waived right participate development commercialization nx right receive royalties giving gilead exclusive rights compound december compound also assigned osi part sale oncology assets iocbrega gilead entered agreements institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega relating certain nucleotide compounds discovered two institutions agreements gilead received exclusive right manufacture use sell nucleotide compounds gilead obligated pay iocbrega percentage net revenues received sales products containing compounds subject minimum royalty payments products covered agreement include vistide adefovir dipivoxil viread exclude tamiflu gilead currently makes quarterly payments iocbrega based percentage vistide viread sales marketing approval received fda adefovir dipivoxil gilead would obligated pay additional amounts iocbrega upon future sales product december agreements iocbrega amended provide reduced royalty rate future sales adefovir dipivoxil viread return upfront payment gilead million upon signing agreement payment recorded longterm prepaid royalty classified noncurrent assets balance sheet december recognized royalty expense expected commercial life viread recognized royalty expense expected commercial life adefovir dipivoxil fda approval obtained sales product commence amortization million payment significant december southern research institute december gilead entered agreement southern research institute giving gilead worldwide rights develop commercialize gs antitumor compound gilead evaluating preclinical studies terms agreement gilead paid southern research institute upfront fee included research development expense december compound assigned osi part sale oncology assets inventories inventories summarized follows thousands december raw materials work process finished goods property plant equipment property plant equipment consist following thousands december building improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction progress less accumulated depreciation amortization investment sale unconsolidated affiliatein july company established proligo llc delaware limited liability company proligo wholly owned subsidiary transferred assets nexstar technology products division proligo proligo supplies nucleic acid peptide synthesis products pharmaceutical biopharmaceutical industry sale use laboratory research reagents therapeutic diagnostic products august company sold interest interest proligo skw americas inc skw payment interest company received million cash interest perseptive biosystems gmbh company hamburg germany hamburg company specializes manufacture nucleoside phosphoramidite monomers interest hamburg company fair market value approximately million addition skw agreed pay company million guaranteed payments discounted gain recognition purposes million performancebased milestones next four years gilead received full million guaranteed payments skw past three years gilead also received performance based milestone payment million included contract revenue part original transaction company contributed million interest hamburg company proligo company recorded million gain connection sale skw contributed million remaining interest hamburg company proligo also connection transaction company proligo agreed proligo would manufacture oligonucleotides required company cost plus fixed percentage company purchased oligonucleotides proligo total million purchases made purchases charged rd expense january october gilead made two additional cash investments proligo total million maintain ownership interest proligo gilead commitments provide additional funding proligo beyond january company accounted investment proligo using equity method accounting net book value investment million december reported noncurrent assets company 's consolidated balance sheet gilead recorded million equity loss proligo prior date sale recognized million equity proligo 's net loss representing share proligo 's loss thirteenmonth period ended december fourth quarter proligo changed fiscal year end december november gilead recorded million equity loss proligo proligo 's fiscal year ended november gilead sold interest proligo degussa corporation million cash proceeds net gilead 's investment proligo reflected million gain sale unconsolidated affiliate longterm obligations longterm obligations consist following thousands december capital lease obligations monthly installments interest rates ranging fixed rate debt monthly installments secured equipment interest rates ranging total longterm obligations less current portion longterm obligations due one year maturities longterm obligations including capital lease obligations follows thousands year thereafter less amount representing interest total terms various debt agreements require company comply certain financial operating covenants december company compliance covenants convertible subordinated notes debentures december gilead issued million convertible subordinated notes due december private offering jp morgan co lehman brothers morgan stanley dean whitter resold notes private institutional investors notes convertible total shares gilead common stock per share conversion price higher gilead 's common stock price note 's issue date notes redeemable whole part option company time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes third quarter gilead issued million convertible subordinated debentures due private offering sbc warburg inc oppenheimer co inc resold debentures group private investors debentures issued pursuant indenture convertible total shares gilead common stock per share debentures redeemable whole part option company time august specified redemption prices plus accrued interest gilead called debentures redemption august cash price per principal amount debentures outstanding plus accrued interest redemption price provided original debenture indenture entire million principal amount debentures outstanding time converted newly issued shares gilead common stock prior august deferred debt issuance costs million related debentures charged additional paid capital connection conversion debentures common stock commitments contingencies leases arrangements company entered various longterm noncancelable operating leases facilities foster city san dimas california leases expire various dates leases two fiveyear renewal options exception one lease foster city expires contains renewal options company operating leases sales marketing administrative facilities europe australia various terms miscellaneous equipment leases rent expense net sublease income company 's operating leases totaled approximately million million million company entered capital leases finance equipment purchases facilities improvements title assets acquired lease lines credit resides lessor company option purchase assets end lease terms fair market value leases remaining terms three years december additional amounts available agreements aggregate noncancelable future minimum rental payments operating capital leases net aggregate future minimum rentals received company noncancelable subleases follows thousands operating leases net years ending december noncancelable subleases capital leases thereafter less amount representing interest total capital lease obligations less current portion capital lease obligations due one year december company placed million bank escrow deposit secure aggregate future payments due one facilities leases contingent liability gilead subleased certain facilities primarily california sublessees default obligations subleases company would primarily liable original lessor total amount due leases december million line credit april maintained million unsecured line credit bears interest floating rate major financial institution terms line credit required maintain certain financial ratios limitations ability incur additional debt engage certain significant transactions line credit included foreign exchange facility expired april renewed foreign exchange facility renew line credit required financial ratios limitations debt transactions foreign exchange facility legal proceedings august company elan corporation plc elan successor company liposome company inc reached settlement settlement agreement companies agreed dismiss legal proceedings involving ambisome gilead 's liposomal formulation amphotericin b settlement agreement elan granted company immunity suit connection worldwide production sales ambisome worldwide right use two patents terms settlement agreement gilead made initial payment elan million required make payments beginning intheir patents terms settlement agreement gilead made initial payment elan million required make payments beginning based ambisome sales next several years payments subject certain minimum maximum amounts company recorded accounting charges million million represented net present value future minimum payments million represented initial cash payment beginning gilead records expense quarter based difference future minimum payments expense recorded addition beginning company recognizing cost goods sold difference minimum maximum payments gilead expect difference future minimum maximum payments elan material company involved time time legal proceedings arising ordinary course business opinion management none matters expected material adverse effect financial position operations company based factors currently known management stockholders ' equity stock split february march gilead completed twoforone stock splits effected form stock dividend stockholders record february february respectively accordingly share per share amounts periods presented restated reflect splits preferred stock company shares authorized preferred stock issuable series company 's board directors board authorized determine designation powers preferences rights series company reserved shares preferred stock potential issuance preferred share purchase rights plan june company issued shares series b convertible preferred stock preferred stock pharmacia approximately million per share july average closing price gilead 's common stock thirty days ended event triggered automatic conversion preferred stock owned pharmacia company 's common stock accordingly preferred stock converted shares common stock price per share july preferred stock outstanding december employee stock purchase plan gilead 's employee stock purchase plan espp employees purchase shares gilead common stock based percentage compensation purchase price per share must equal least lower percent market value date offered date purchased total shares common stock reserved issuance espp december shares total shares reserved issued espp shares december stock option plans december gilead adopted incentive stock option plan supplemental stock option plan issuance common stock employees consultants scientific advisors april board approved granting certain additional nonqualified stock options terms conditions substantially similar granted supplemental stock option plan none options described exercise prices less fair value underlying stock date grant options vest five years pursuant formula determined board expire ten years shares available grant future options plans november gilead adopted stock option plan plan issuance common stock employees consultants options issued plan shall discretion board either incentive stock options nonqualified stock options may plan amended exercise price stock options must least equal fair value gilead 's common stock date grant options vest five years pursuant formula determined board expire ten years may stockholders approved amendment plan increased total number authorized shares plan december shares available grant future options plan november gilead adopted nonemployee directors ' stock option plan directors ' plan issuance common stock nonemployee directors pursuant predetermined formula exercise price options granted directors ' plan must least equal fair value gilead 's common stock date grant options vest five years date grant quarterly five percent installments expire ten years december shares available grant future options directors ' plan stock plans assumed gilead merger nexstar include stock option plan plan incentive stock plan director option plan collectively nexstar plans options pursuant stock option plan incentive stock plan issued outstanding july converted options purchase gilead common stock result merger remain subject original terms conditions shares available grant future options nexstar plans nexstar 's plan allows certain option holders execute cashless exercises options cashless exercise transaction option holder specifies many shares exercised company issues specified number shares less number would required cover exercise price based fair value stock exercise date several option holders performed cashless exercises result option awards considered variable therefore company recognized compensation expense million million million amount million relates exercised options remaining million relates options remain outstanding plan december following table summarizes activity gilead nexstar stock option plans three years period ended december option grants presented table exercise prices less fair value underlying stock grant date shares thousandsyear ended december weighted weighted weighted average average average exercise exercise exercise shares price shares price shares price outstanding beginning year granted forfeited exercised outstanding end year exercisable end year weighted average fair value options granted following summary gilead options outstanding options exercisable december options thousands options outstanding options exercisable weighted average weighted remaining average weighted options contractual exercise options average range exercise prices outstanding life years price exercisable exercise price total stockholders ' equity pro forma disclosures table presents combined net income loss basic diluted net income loss per common share compensation cost gilead nexstar stock option plans espp determined based estimated fair value awards plans grant purchase date year ended december pro forma net income loss thousands pro forma net income loss per common sharebasic pro forma net income loss per common sharediluted fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option pricing model company used multiple option approach following assumptions year ended december expected life years vesting date stock options espp discount rate stock options espp volatility expected dividend yield weighted average estimated fair value espp shares purchased preferred share purchase rights plan november company adopted preferred share purchase rights plan plan provides distribution preferred stock purchase right dividend share gilead common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group company 's common stock purchase rights permit holders holder purchase gilead common stock discount market price time upon payment specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price per purchase right purchase rightshave voting privileges attached automatically trade gilead common stock october board directors approved amendment purchase rights plan amendment provided among things increase exercise price right plan extension term plan november october acceleration stock options december completed sale oncology assets osi part transaction accelerated approximately options purchase gilead common stock value million see note discussion comprehensive income loss following reclassification adjustments required avoid doublecounting net realized gains losses sales securities previously included comprehensive income prior sales securities thousands year ended december net gain loss sales securities included interest income comprehensive income net unrealized gain loss arising year reclassification adjustment net unrealized gain loss reported comprehensive income balance accumulated comprehensive income loss reported balance sheet consists following components thousands december net unrealized gain availableforsale securities net unrealized gain cash flow hedges net foreign currency translation loss accumulated comprehensive income loss disclosures segments enterprise related information company determined one reportable segment management organized business along functional lines product sales consist following thousands year ended december ambisome viread following table summarizes revenues external customers collaborative partners geographic region revenues attributed countries based location customer collaborative partner thousands year ended december united states united kingdom germany italy spain france switzerland european countries countries consolidated total revenues december net book value company 's property plant equipment million approximately assets located united states december net book value property plant equipment million approximately assets located united states product sales one distributor exceed total revenues product sales one distributor accounted approximately total revenues total revenues fujisawa healthcare inc included product sales royalties approximately total revenues revenues roche including royalties milestone payments reimbursement research development expenses exceed total revenues account approximately total revenues income taxes company deferred provision income taxes current provision income taxes consisted following thousands year ended december current provision federal state foreign foreign pretax income loss million million million difference provision taxes income amount computed applying federal statutory income tax rate income provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle explained thousands year ended december income loss provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle tax federal statutory rate benefitted unbenefitted losses federal alternative minimum taxes december company us federal net operating loss carryforwards million state net operating loss carryforwards million federal net operating loss carryforwards expire various dates beginning utilized state net operating loss carryforwards expire various dates utilized addition company federal state tax credit carryforwards approximately million million respectively expire years utilization net operating losses credits may subject annual limitation due ownership change limitations provided internal revenue code similar state provisions annual limitation may result expiration net operating losses credits utilization income taxes continued deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components company 's deferred tax assets liabilities december follows thousands december net operating loss carryforwards research credits capitalized rd california net total deferred tax assets valuation allowance net deferred tax assets recognized valuation allowance decreased million year ended december increased million year ended december approximately million valuation allowance december relates tax benefits stock option deductions credited additional paidin capital realized retirement savings plan december company maintains one retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code prior january gilead maintained two separate retirement savings plans one plan primarily covered former nexstar employees nexstar plan plan primarily covered gilead 's remaining eligible employees gilead plan nexstar plan employee contributions could exceed eligible annual compensation addition nexstar plan included company match employee contributions maximum contributions annual maximum company match december approximately million representing shares gilead common stock held nexstar plan trust plan participants effective january nexstar plan terminated combined gilead plan shares gilead common stock held nexstar plan subsequently liquidated proceeds deposited various investment options available gilead plan gilead plan employees may contribute eligible annual compensation effective january gilead began making matching contributions gilead plan company contributes employee 's first contributions annual maximum company match company 's total matching contribution gilead plan million combined million plans million nexstar plan related party transactions december chairman gilead 's board directors senior advisor investment fund owns controlling interest pharmaresearch corporation contract research organization performs services connection clinical studies gilead 's payments pharmaresearch corporation million million quarterly results unaudited following table thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues total costs expenses income loss cumulative effect change accounting principle cumulative effect change accounting principle net loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted st quarter nd quarter rd quarter th quarter total revenues total costs expenses loss cumulative effect change accounting principle cumulative effect change accounting principle net loss basic diluted amounts per share loss cumulative effect change accounting principle cumulative effect change accounting principle net loss year ended december gilead adopted sfas reported cumulative effect change accounting principle first quarter year ended december adopted sab reported cumulative effect change accounting principle accounting change adopted fourth quarter effective first quarter first three quarters restated retroactively reflect change february march gilead completed twoforone stock splits effected form stock dividend stockholders record february february respectively accordingly share per share amounts periods presented restated reflect splits diluted net income per common share fourth quarter includes effects stock options million convertible subordinated notes december completed sale oncology assets osi company recorded nonoperating gain million fourth quarter result transaction gilead sciences inc schedule ii valuation qualifying accounts additions balance balance beginning charged charged end period expense deductions period year ended december allowance doubtful accounts valuation allowance deferred tax assets year ended december allowance doubtful accounts valuation allowance deferred tax assets year ended december allowance doubtful accounts valuation allowance deferred tax assets charged current tax expense charged deferred tax benefit